[
    {
        "src_smiles": "c1ccc(-c2cc(NCc3cccnc3)n3nccc3n2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central imidazo[1,2-b]pyridazine heterocyclic core. This core is substituted at one position with a phenyl group and at another position with a (pyridin-3-ylmethyl)amine linker group (-NHCH2-pyridine). Key features include the fused heterocyclic system, the aromatic phenyl ring, the flexible amine linker, and the pyridine ring.\",\n    \"Property_Analysis\": \"GSK3-beta is a serine/threonine kinase. Inhibitors typically target the ATP-binding site. The source molecule possesses potential pharmacophoric features for kinase inhibition: hydrogen bond acceptors (N atoms in imidazopyridazine and pyridine), a hydrogen bond donor (amine NH), and hydrophobic regions (phenyl and pyridine rings, imidazopyridazine core). These groups could interact with hinge residues, hydrophobic pockets, and other residues within the GSK3-beta active site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The unsubstituted phenyl ring might offer suboptimal hydrophobic interactions within the pocket it occupies. Furthermore, the specific positioning and electronic nature of the pyridine nitrogen and the amine linker might not be perfectly aligned for strong hydrogen bonding interactions with key residues (e.g., hinge region Val135, Asp200) in the GSK3-beta active site, potentially limiting binding affinity and selectivity.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance hydrophobic interactions and potentially improve binding affinity, the phenyl ring can be substituted. Adding a halogen, such as Chlorine, at the para-position is a common strategy in kinase inhibitor design. This modification can improve occupancy of the hydrophobic pocket and potentially modulate electronic properties influencing interactions or pharmacokinetic parameters without significantly increasing size.\",\n    \"Final_Target_Molecule\": \"c1cc(Cl)ccc1-c1cc(NCc2cccnc2)n2nccc2n1\"\n  }\n]"
    },
    {
        "src_smiles": "O=c1cc(Br)c2cccc([N+](=O)[O-])c2[nH]1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, O=c1cc(Br)c2cccc([N+](=O)[O-])c2[nH]1 (6-bromo-4-nitro-1,3-dihydro-2H-indol-2-one), features an oxindole core. Key functional groups include a lactam (potential H-bond donor/acceptor), a bromine atom at position 6 (halogen bonding potential, electron-withdrawing), and a nitro group at position 4 (strong electron-withdrawing, potential metabolic liability).\",\n    \"Property_Analysis\": \"The oxindole core is present in some kinase inhibitors. The lactam NH and C=O can interact with the hinge region of GSK3-beta. The aromatic ring can participate in hydrophobic interactions. The substituents (Br, NO2) modulate electronic properties and provide potential interaction points but may not be optimal.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The nitro group (position 4) is often associated with toxicity and poor metabolic stability, potentially limiting its use as a drug candidate. The positioning and nature of both the nitro group and the bromine atom (position 6) might not be ideal for specific, high-affinity interactions within the ATP-binding site of GSK3-beta.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition and drug-like properties, the nitro group at position 4 will be removed (replaced with H) to mitigate toxicity concerns. The bromine atom at position 6 will be replaced with a methylsulfonamide group (-NHSO2CH3), which is common in kinase inhibitors and can form favorable hydrogen bond interactions within the kinase active site, potentially improving affinity and selectivity.\",\n    \"Final_Target_Molecule\": \"CS(=O)(=O)Nc1ccc2[nH]c(=O)cc2c1\"\n  }\n]"
    },
    {
        "src_smiles": "O=C(O)c1ccccc1Nc1ccnc(N2CCCCC2)n1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, O=C(O)c1ccccc1Nc1ccnc(N2CCCCC2)n1, features an aminopyrimidine core, which is a common scaffold in kinase inhibitors. It has a 2-(carboxyphenyl)amino substituent at one position and a piperidino substituent at another position on the pyrimidine ring.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves hydrogen bonding interactions with the kinase hinge region (e.g., Val135 backbone) and occupation of the ATP binding pocket. The aminopyrimidine core, particularly the aniline NH and pyrimidine nitrogens, can participate in these hydrogen bonds. The piperidine and carboxyphenyl groups occupy adjacent regions of the binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 2-carboxylic acid group on the phenyl ring might introduce unfavorable polarity or steric hindrance, or it might not be optimally positioned for potent interactions within the GSK3-beta active site compared to other substituents frequently found in inhibitors. Its acidity could also lead to poor pharmacokinetic properties.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, the 2-carboxylic acid group can be replaced. Substituting it with a group that maintains or improves binding interactions while potentially enhancing pharmacokinetic properties is desirable. A common strategy is to replace it with a less polar, potentially bioisosteric group or a group known to interact favorably in related kinase inhibitors, such as a halogen or a small hydrophobic group. Replacing the carboxyphenyl group with a 4-fluorophenyl group introduces a substituent often found to enhance binding affinity and metabolic stability in kinase inhibitors without the high polarity and acidity of the carboxylic acid.\",\n    \"Final_Target_Molecule\": \"Fc1ccc(Nc2ccnc(N3CCCCC3)n2)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1cc2ncnc(N(C)c3ccc(C)c(Cl)c3)c2cc1OC",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, COc1cc2ncnc(N(C)c3ccc(C)c(Cl)c3)c2cc1OC, features a 6,7-dimethoxyquinazoline core. The C4 position of the quinazoline is substituted with a tertiary amine: N-methyl-N-(3-chloro-4-methylphenyl)amine.\",\n    \"Property_Analysis\": \"Quinazoline derivatives are established scaffolds for kinase inhibitors, often interacting with the ATP binding site. The C4-amino substituent is critical for hinge binding interactions. The N-methyl group and the specific substitution pattern (3-chloro, 4-methyl) on the N-phenyl ring determine binding affinity and selectivity by interacting with a hydrophobic pocket. The 6,7-dimethoxy groups modulate solubility, metabolic stability, and potentially interact with the binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The N-methyl group may introduce steric hindrance or prevent the formation of a crucial hydrogen bond often observed between secondary amines (-NH-) at this position and the kinase hinge region. The 3-chloro-4-methylphenyl group might not provide optimal hydrophobic interactions or shape complementarity within the GSK3-beta active site compared to other substitution patterns. The dimethoxy groups are susceptible to O-demethylation, potentially leading to metabolic instability.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition: 1. Replace the N-methyl group with a hydrogen atom (-H) to facilitate hydrogen bonding with the kinase hinge region, transforming the tertiary amine into a secondary amine (-NH-). 2. Replace the 3-chloro-4-methylphenyl group with a substituent known to favor GSK3-beta binding, such as a 4-fluorophenyl group. Fluorine substitution is common in kinase inhibitors to enhance binding affinity and improve metabolic stability.\",\n    \"Final_Target_Molecule\": \"COc1cc2ncnc(Nc3ccc(F)cc3)c2cc1OC\"\n  }\n]"
    },
    {
        "src_smiles": "COc1ccc(-c2cc3c(NCc4ccccc4)ncnc3o2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule consists of a central oxazolo[5,4-d]pyrimidine core. A methoxy-substituted phenyl ring is attached at position 2 of the oxazole ring. The pyrimidine ring is substituted at position 6 with a benzylamine group.\",\n    \"Property_Analysis\": \"The oxazolopyrimidine core resembles the purine scaffold, a common feature in ATP-competitive kinase inhibitors, suggesting potential interaction with the ATP binding site of GSK3-beta. The substituted phenyl ring and the benzylamine group likely occupy hydrophobic pockets and contribute to binding affinity. Nitrogen atoms in the core and the amine linker can act as hydrogen bond acceptors/donors.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The flexibility of the benzylamine linker (CH2 bridge) might lead to an entropic penalty upon binding. The methoxy substituent on the phenyl ring may not be optimal for potency or selectivity; other substituents might offer better interactions within the binding pocket. The overall scaffold and substitution pattern might not fully optimize interactions with key residues (e.g., hinge region, hydrophobic pockets) in the GSK3-beta active site.\",\n    \"Optimization_for_Source_Molecule\": \"To improve binding affinity and potentially reduce conformational flexibility penalty, the benzylamine linker will be replaced by a direct aniline linkage (-NH-phenyl). Additionally, the electron-donating methoxy group on the terminal phenyl ring will be replaced with an electron-withdrawing and potentially halogen-bonding Chlorine atom, a common modification to enhance potency in kinase inhibitors.\",\n    \"Final_Target_Molecule\": \"Clc1ccc(-c2cc3c(Nc4ccccc4)ncnc3o2)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "CNc1nn2c(C)cc(CO)nc2c1S(=O)(=O)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrazolo[1,5-a]pyrimidine core. Key substituents include a methylamino group (-NHCH3) on the pyrazole ring, a methyl group (-CH3) and a hydroxymethyl group (-CH2OH) on the pyrimidine ring, and a phenylsulfonyl group (-SO2Ph) attached to the pyrimidine ring.\",\n    \"Property_Analysis\": \"Pyrazolo[1,5-a]pyrimidines are known scaffolds for kinase inhibitors, including GSK3-beta. The sulfonyl group likely interacts with the hinge region of the ATP binding site. The methylamino and hydroxymethyl groups are positioned to potentially interact with solvent or specific amino acid residues, influencing potency and selectivity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The phenylsulfonyl group might not provide optimal interactions within the GSK3-beta active site; its size, hydrophobicity, and electronic properties could be suboptimal for potency or selectivity. Additionally, the existing polar groups (methylamino, hydroxymethyl) might not be perfectly positioned or suited for maximizing hydrogen bonding or other favorable interactions required for high-affinity binding.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, the phenylsulfonyl group will be replaced. Substituting it with a morpholinosulfonyl group (-SO2N(CH2CH2)2O) can introduce different steric and electronic properties, potentially improve solubility, and offer new hydrogen bond acceptor capabilities via the morpholine oxygen and sulfonyl oxygens, potentially leading to enhanced binding affinity and improved pharmacokinetic properties.\",\n    \"Final_Target_Molecule\": \"CNc1nn2c(C)cc(CO)nc2c1S(=O)(=O)N1CCOCC1\"\n  }\n]"
    },
    {
        "src_smiles": "Nc1nonc1-c1nc2ccccc2n1Cc1ccncc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule consists of three main fragments linked together: 1) An amino-oxadiazole ring (Nc1nonc1-). 2) An imidazo[1,2-a]pyridine core (-c1nc2ccccc2n1-). 3) A (pyridin-4-yl)methyl group (-Cc1ccncc1) attached to the nitrogen of the imidazo[1,2-a]pyridine.\",\n    \"Property_Analysis\": \"GSK3-beta is a kinase. Inhibitors typically bind to the ATP pocket. The imidazo[1,2-a]pyridine core likely acts as a hinge-binding motif. The amino-oxadiazole provides hydrogen bond donor/acceptor capabilities and occupies one sub-pocket. The (pyridin-4-yl)methyl group occupies another pocket, with the pyridine nitrogen acting as a hydrogen bond acceptor and contributing polarity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The (pyridin-4-yl)methyl group introduces significant basicity via the pyridine nitrogen, which can lead to poor pharmacokinetic properties (e.g., rapid metabolism, hERG liability) or suboptimal interactions within the binding pocket. The flexibility of the methylene linker might also lead to an entropic penalty upon binding. The specific interactions of the amino-oxadiazole moiety might not be optimal for potent inhibition.\",\n    \"Optimization_for_Source_Molecule\": \"To address the limitations associated with the basicity and potential ADME liabilities of the pyridine ring, the (pyridin-4-yl)methyl group will be replaced with a 4-fluorobenzyl group. This removes the basic nitrogen, introduces a fluorine atom which can potentially improve binding affinity and metabolic stability, and maintains a similar size and shape profile for occupying the corresponding sub-pocket. The core scaffold and the amino-oxadiazole group are retained in this optimization step.\",\n    \"Final_Target_Molecule\": \"Nc1nonc1-c1nc2ccccc2n1Cc1ccc(F)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(C)=Cc1ccc2cc(NC(=O)C3CC3)ncc2c1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a 1,6-naphthyridine core. An isobutenyl group is attached at position 4 of the naphthyridine ring system (via the fused benzene ring). An amide group links the naphthyridine core at position 7 to a cyclopropyl group.\",\n    \"Property_Analysis\": \"Naphthyridine cores are recognized scaffolds in kinase inhibitors, including GSK3-beta inhibitors. The amide group can act as a hydrogen bond donor/acceptor, potentially interacting with the hinge region of the kinase. The isobutenyl and cyclopropyl groups explore hydrophobic pockets within the ATP binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The isobutenyl group might confer excessive lipophilicity or suboptimal interactions within its binding pocket, potentially affecting potency or selectivity. The small cyclopropyl group might not provide sufficient interactions or could be replaced by groups offering better interactions (e.g., pi-stacking, polar interactions).\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve interactions and optimize physicochemical properties, replace the isobutenyl group with a smaller, less lipophilic methyl group. Replace the cyclopropyl group with a phenyl ring to explore potential pi-stacking interactions within the binding site, a common feature in kinase inhibitors.\",\n    \"Final_Target_Molecule\": \"Cc1ccc2cc(NC(=O)c3ccccc3)ncc2c1\"\n  }\n]"
    },
    {
        "src_smiles": "CCc1[nH]c2ccc(OC)cc2c1C1=CCNCC1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features an indole core substituted at position 2 with an ethyl group and fused benzene ring bearing a methoxy group. Position 3 of the indole is attached to a 1,2,3,6-tetrahydropyridine ring via a carbon-carbon bond.\",\n    \"Property_Analysis\": \"Indole scaffolds are common privileged structures in kinase inhibitors, including GSK3-beta inhibitors. The nitrogen atoms in the indole and tetrahydropyridine rings can potentially form hydrogen bonds. The ethyl and methoxy groups contribute to lipophilicity and might interact with hydrophobic pockets in the enzyme active site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 1,2,3,6-tetrahydropyridine ring introduces conformational flexibility and a potentially basic secondary amine which might affect pharmacokinetic properties or specific binding interactions. The specific substitution pattern (ethyl, methoxy, tetrahydropyridine) might not be optimal for potency or selectivity against GSK3-beta.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially enhance binding interactions and improve physicochemical properties, the flexible and basic tetrahydropyridine ring can be replaced with a more rigid and planar aromatic heterocycle, such as pyridine. Replacing the tetrahydropyridin-4-yl group with a pyridin-4-yl group introduces a defined aromatic system and a hydrogen bond acceptor nitrogen, which could lead to improved interactions within the GSK3-beta active site.\",\n    \"Final_Target_Molecule\": \"CCc1[nH]c2ccc(OC)cc2c1c1ccncc1\"\n  }\n]"
    },
    {
        "src_smiles": "Cc1ccc(-c2nnc(SCc3ccccc3)o2)c(O)c1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, Cc1ccc(-c2nnc(SCc3ccccc3)o2)c(O)c1, features a central 1,3,4-oxadiazole ring substituted at position 5 with a 4-methyl-2-hydroxyphenyl group and at position 2 with a (benzylthio) group.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often require specific interactions within the ATP-binding site, typically involving hydrogen bonds with the hinge region (e.g., Val135), salt bridges, and hydrophobic interactions. The source molecule possesses potential hydrogen bond donors (phenol OH) and acceptors (oxadiazole N and O atoms, potentially S) and aromatic rings for hydrophobic/pi-stacking interactions.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The benzylthio group might lack specific favorable interactions within the GSK3-beta active site. The flexibility of the thioether linkage and the benzyl group might lead to an entropic penalty upon binding. The position and orientation of the phenol group might not be optimal for strong hydrogen bonding with key residues like Asp200 or the hinge region. The thioether is also potentially metabolically labile.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, replace the flexible and potentially suboptimal benzylthio group with a group known to interact favorably with the kinase hinge region. Introducing a nitrogen atom capable of hydrogen bonding is a common strategy. Replacing the -S-CH2-Ph group with an amino-pyridine moiety, specifically a 4-pyridylamino group (-NH-pyridine), could introduce a crucial hydrogen bond donor (NH) and acceptor (pyridine N) aimed at interacting with the hinge region (e.g., Val135 backbone carbonyl). This modification also increases rigidity.\",\n    \"Final_Target_Molecule\": \"Cc1ccc(-c2nnc(Nc3ccncn3)o2)c(O)c1\"\n  }\n]"
    },
    {
        "src_smiles": "O=C(O)CSc1nonc1-c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, O=C(O)CSc1nonc1-c1ccccc1, features a 1,2,4-oxadiazole core linked to a phenyl ring on one side and a (carboxymethyl)sulfanyl group (-SCH2COOH) on the other. Key components include the acidic carboxylic group, a flexible thioether methylene linker, the heterocyclic oxadiazole ring, and an unsubstituted phenyl ring.\",\n    \"Property_Analysis\": \"GSK3-beta is a serine/threonine kinase. Inhibitors typically target the ATP-binding site, forming hydrogen bonds with hinge residues (e.g., Val135) and engaging in hydrophobic interactions. The oxadiazole nitrogen atoms could potentially interact with the hinge region. The phenyl ring can occupy a hydrophobic pocket. The carboxylic acid group might form hydrogen bonds or salt bridges, but its flexibility and position might not be optimal.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The flexible -SCH2COOH side chain might adopt conformations unfavorable for strong binding. The carboxylic acid's acidity could lead to poor cell permeability and potential off-target interactions. The thioether linkage is susceptible to metabolic oxidation. The unsubstituted phenyl ring lacks specific interactions that could enhance potency and selectivity. The overall structure might lack the precise geometry and interaction points needed for high-affinity GSK3-beta inhibition.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, replace the flexible, acidic -SCH2COOH group with a more rigid and typical kinase hinge-binding motif, such as a primary amide (-CONH2) directly attached to the oxadiazole ring. This offers potential hydrogen bond donors/acceptors in a more defined position. Substitute the phenyl ring with electron-withdrawing groups (e.g., chlorine) to enhance hydrophobic interactions and potentially improve pharmacokinetic properties. Specifically, replacing -SCH2COOH with -C(=O)NH2 and adding a para-chloro substituent to the phenyl ring aims to improve binding affinity and metabolic stability.\",\n    \"Final_Target_Molecule\": \"O=C(N)c1nonc1-c1ccc(Cl)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "CN(C)c1ccc(C(=O)NCc2ccccc2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, CN(C)c1ccc(C(=O)NCc2ccccc2)cc1, features a central amide linker connecting an N,N-dimethylaniline ring (electron-rich aromatic system) to a benzyl group (hydrophobic aromatic system). The dimethylamino group is para to the amide linkage.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often contain heterocyclic scaffolds capable of forming hydrogen bonds with the kinase hinge region (e.g., interacting with Val135). The source molecule lacks a canonical hinge-binding motif. The amide group can act as H-bond donor/acceptor, but the overall structure might not fit optimally into the ATP-binding pocket. The N,N-dimethylaniline and benzyl groups provide bulk and hydrophobicity but may not occupy key binding pockets effectively.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The primary limitation is the absence of a strong, well-oriented hinge-binding moiety typically found in potent GSK3-beta inhibitors. The N,N-dimethylaniline ring is not a common hinge-binding element. The flexibility of the molecule and the specific nature of the substituents might lead to suboptimal interactions or steric clashes within the active site.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, the N,N-dimethylaniline moiety should be replaced with a heterocycle known to interact effectively with the kinase hinge region. A 2-aminothiazole ring is a common fragment in kinase inhibitors that can provide appropriate hydrogen bonding interactions. Replacing the N,N-dimethylaniline group with a 2-aminothiazole attached to the carbonyl group could introduce the necessary hinge-binding interactions while retaining the amide and benzyl portions for potential hydrophobic interactions.\",\n    \"Final_Target_Molecule\": \"O=C(NCc1ccccc1)c1csc(N)n1\"\n  }\n]"
    },
    {
        "src_smiles": "Nc1ccccc1NC(=O)c1ccc(CNc2ncccn2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, Nc1ccccc1NC(=O)c1ccc(CNc2ncccn2)cc1, consists of an aniline moiety linked via an amide bond to a central phenyl ring, which is further connected through a methylene linker (-CH2-) to a pyrazine ring.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often contain a hinge-binding heterocyclic motif (like pyrazine, pyridine, pyrimidine) connected via a linker to a larger hydrophobic scaffold. The amide group provides structural rigidity and potential hydrogen bonding interactions. The pyrazine ring is expected to interact with the hinge region of the GSK3-beta ATP binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The pyrazine ring is a relatively weak hinge binder compared to other heterocycles commonly found in potent GSK3 inhibitors (e.g., pyridine, pyrrolopyrimidine). The aniline group (Nc1ccccc1) can be metabolically liable (oxidation) and might not provide optimal hydrophobic interactions. The flexibility of the -CH2- linker might also lead to entropic penalties upon binding.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, the weakly binding pyrazine will be replaced with a pyridine ring, known to form stronger interactions with the kinase hinge region. The flexible -CH2- linker will be removed and replaced by a direct amine linkage (-NH-) which can also provide an additional hydrogen bond interaction. The metabolically labile aniline group will be replaced with a 4-chlorophenyl group to enhance metabolic stability and potentially improve hydrophobic interactions.\",\n    \"Final_Target_Molecule\": \"Clc1ccc(C(=O)Nc2ccc(Nc3ccncc3)cc2)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The molecule features a 6-methoxypyrazolo[3,4-b]pyridine core, which is a common hinge-binding motif in kinase inhibitors. This core is connected via a urea linker (-NH-C(=O)-NH-) to a chiral 1-phenylethyl group.\",\n    \"Property_Analysis\": \"The pyrazolo[3,4-b]pyridine core likely interacts with the hinge region of GSK3-beta via hydrogen bonds (especially the pyrazole N-H). The urea group provides additional hydrogen bond donors/acceptors. The 1-phenylethyl group likely occupies a hydrophobic pocket adjacent to the ATP binding site. The methoxy group may interact with the ribose pocket or solvent.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The unsubstituted phenyl ring might not optimally fill the hydrophobic pocket or lack specific interactions for enhanced potency or selectivity. The methoxy group's contribution might be suboptimal compared to other potential substituents. The stereochemistry at the chiral center is undefined, and likely only one enantiomer is highly active.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance binding affinity, introduce a substituent on the phenyl ring to probe for additional interactions within the pocket. A para-fluoro substituent is often beneficial for potency and metabolic stability. Specify the stereochemistry, assuming the (R)-enantiomer might be more active, as commonly observed for similar motifs.\",\n    \"Final_Target_Molecule\": \"COc1n[nH]c2cc(NC(=O)N[C@@H](C)c3ccc(F)cc3)ncc12\"\n  }\n]"
    },
    {
        "src_smiles": "CCC(C)Nc1ncnc2cc(OC)c(OC)cc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, CCC(C)Nc1ncnc2cc(OC)c(OC)cc12, is 4-(sec-butylamino)-6,7-dimethoxyquinazoline. It features a quinazoline core, which is a bicyclic system consisting of fused benzene and pyrimidine rings. A sec-butylamino group is attached at the C4 position of the pyrimidine ring. Two methoxy groups (-OCH3) are present at positions C6 and C7 of the fused benzene ring.\",\n    \"Property_Analysis\": \"The quinazoline scaffold is prevalent in kinase inhibitors, suggesting potential interaction with the ATP-binding site of kinases like GSK3-beta. The nitrogen atoms (N1, N3) in the pyrimidine ring can act as hydrogen bond acceptors, potentially interacting with the hinge region of GSK3-beta. The 6,7-dimethoxy groups contribute to the electronic properties and potential interactions within the binding pocket. The sec-butylamino group at C4 provides a lipophilic interaction point and occupies space within the ATP pocket.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 4-alkylamino substituent (sec-butylamino) might offer suboptimal interactions compared to aryl amino groups often found in potent kinase inhibitors. The sec-butyl group's flexibility and shape may not be ideal for fitting the specific hydrophobic pocket of GSK3-beta, potentially limiting potency. Furthermore, quinazoline derivatives can lack selectivity, potentially inhibiting other kinases. The methoxy groups could be metabolically labile (O-demethylation).\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, the primary optimization focuses on the C4 substituent, which directly interacts with the ATP binding site. Replace the sec-butylamino group with an anilino group, a common motif in potent quinazoline-based kinase inhibitors. Specifically, introduce a 3-chloroanilino group. The phenyl ring provides pi-stacking opportunities, the amino group acts as a hydrogen bond donor/acceptor linker, and the chlorine atom at the meta position can potentially occupy a specific sub-pocket within the GSK3-beta active site and modulate electronic properties, aiming for increased potency and potentially selectivity.\",\n    \"Final_Target_Molecule\": \"COc1cc2c(cc1OC)ncnc2Nc1cccc(Cl)c1\"\n  }\n]"
    },
    {
        "src_smiles": "COC(=O)CSc1nc(-c2ccc(F)cc2)c(-c2ccncc2)[nH]1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central imidazole ring substituted at position 2 with a methyl thiocarboxylate group (COC(=O)CS-), at position 4 with a 4-fluorophenyl group, and at position 5 with a 4-pyridyl group. The imidazole nitrogen is protonated (nH). Key features include the imidazole core, two aromatic substituents, a thioether linkage, and a methyl ester group.\",\n    \"Property_Analysis\": \"Imidazole derivatives substituted with aryl groups are known scaffolds for kinase inhibition, including GSK3-beta. The 4-pyridyl nitrogen can act as a hydrogen bond acceptor, potentially interacting with the kinase hinge region. The 4-fluorophenyl group likely occupies a hydrophobic pocket. The methyl thiocarboxylate side chain contributes to the overall physicochemical profile and might interact with solvent-exposed regions or specific subpockets, but its role in potency is less defined compared to the core structure.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The primary limitation is the methyl ester group (COC(=O)). Esters are generally susceptible to hydrolysis by esterase enzymes in vivo, leading to poor metabolic stability and potentially limiting the drug's half-life and bioavailability. This limits its potential as a therapeutic agent targeting GSK3-beta.\",\n    \"Optimization_for_Source_Molecule\": \"To address the metabolic instability of the ester, it can be replaced with a more stable bioisostere. An amide group, specifically an N,N-dimethylamide, is a common replacement. Replacing the methyl ester (COC(=O)) with an N,N-dimethylcarbamoyl group (CN(C)C(=O)) retains similar steric bulk and electronic properties but significantly enhances resistance to hydrolysis, potentially improving pharmacokinetic properties while aiming to maintain or improve GSK3-beta inhibitory activity.\",\n    \"Final_Target_Molecule\": \"CN(C)C(=O)CSc1nc(-c2ccc(F)cc2)c(-c2ccncc2)[nH]1\"\n  }\n]"
    },
    {
        "src_smiles": "Cc1cccc2[nH]c(-c3ccccn3)nc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, Cc1cccc2[nH]c(-c3ccccn3)nc12 (8-methyl-2-(pyridin-2-yl)imidazo[1,2-a]pyridine), features an imidazo[1,2-a]pyridine core. A methyl group is attached at the 8-position of the fused benzene ring, and a pyridine-2-yl group is attached at the 2-position of the imidazole ring. The structure contains nitrogen atoms capable of acting as hydrogen bond acceptors and a potentially weakly donating NH group within the aromatic system.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition typically involves interactions with the ATP-binding site. Key interactions often include hydrogen bonding with the hinge region residues (e.g., Val135) and occupation of hydrophobic pockets. The imidazopyridine core and the pyridine substituent provide a heterocyclic framework common in kinase inhibitors. The nitrogen atoms, particularly in the pyridine and imidazole rings, can serve as hydrogen bond acceptors.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The source molecule might exhibit suboptimal binding affinity due to several factors. The pyridine-2-yl group may not provide optimal interactions within the relevant subpockets of the GSK3-beta active site. The methyl group at the 8-position might introduce steric hindrance or lack favorable interactions, potentially limiting potency or selectivity. The overall hydrogen bonding pattern might be insufficient for strong hinge binding.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, modifications target key interaction points. Replacing the pyridine-2-yl group with a pyrimidine-4-yl group is a common strategy, as the pyrimidine motif is known to form strong hydrogen bonds with the hinge region of kinases, including GSK3-beta (mimicking the adenine part of ATP). Additionally, replacing the 8-methyl group with a chlorine atom can potentially improve potency through favorable halogen interactions or by altering electronic properties and conformation without adding significant bulk.\",\n    \"Final_Target_Molecule\": \"Clc1cccc2[nH]c(-c3cncnc3)nc12\"\n  }\n]"
    },
    {
        "src_smiles": "CN1CCC(c2c[nH]c3ccc(N=C(N)c4cccs4)cc23)CC1",
        "prop": "gsk",
        "json_results": "[{\n  \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features an N-methylpiperidine ring connected to a pyrrolo[2,3-f]quinoline core. A thiophenylguanidine group is attached to the quinoline part of the fused system.\",\n  \"Property_Analysis\": \"The molecule contains potential hydrogen bond donors and acceptors (guanidine, pyrrole NH, piperidine N) and a heterocyclic scaffold, features often found in kinase inhibitors. The guanidine group can interact strongly with kinase hinge regions or specific residues like Aspartic acid. The pyrroloquinoline provides a rigid core.\",\n  \"Limitation_in_Source_Molecule_for_Property\": \"The guanidine group, while capable of strong interactions, confers high basicity, which can lead to poor permeability, potential toxicity, and off-target effects (e.g., hERG interaction). The overall structure might not have optimal geometry or interactions within the ATP binding pocket of GSK3-beta.\",\n  \"Optimization_for_Source_Molecule\": \"Replace the highly basic thiophenylguanidine group with a less basic bioisostere known to interact favorably with kinase active sites, such as an aminopyrimidine group. This modification aims to retain key hydrogen bonding interactions while improving pharmacokinetic properties and potentially selectivity. Specifically, replace the N=C(N)c1cccs1 moiety with a 5-(2-aminopyrimidinyl) group.\",\n  \"Final_Target_Molecule\": \"CN1CCC(c2c[nH]c3ccc(cc23)c4cncc(n4)N)CC1\"\n}]"
    },
    {
        "src_smiles": "COc1cc(OC)c(-c2ccnc(N)n2)c(OC)c1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, COc1cc(OC)c(-c2ccnc(N)n2)c(OC)c1 (4-(2,4,6-trimethoxyphenyl)pyrimidin-2-amine), features a 2-aminopyrimidine core substituted at the 4-position with a 2,4,6-trimethoxyphenyl ring. The 2-amino group on the pyrimidine is a potential hydrogen bond donor/acceptor. The trimethoxyphenyl ring is electron-rich and sterically demanding due to the three methoxy groups.\",\n    \"Property_Analysis\": \"The 2-aminopyrimidine scaffold is a known hinge-binding motif present in many kinase inhibitors, suggesting potential interaction with the ATP-binding site of GSK3-beta. The trimethoxyphenyl group occupies the pocket extending from the hinge region, contributing to binding affinity primarily through hydrophobic and van der Waals interactions.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The bulky and conformationally restricted trimethoxyphenyl group may not optimally fit the specific contours of the GSK3-beta active site. The methoxy groups increase lipophilicity but might introduce metabolic liabilities or fail to establish specific favorable interactions (e.g., hydrogen bonds) within the pocket, potentially limiting overall potency and selectivity.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, replace the 2,4,6-trimethoxyphenyl group with a fragment known to interact favorably with kinase active sites, such as an indole ring. An indole moiety can offer improved shape complementarity, potential for pi-stacking interactions, and hydrogen bonding capabilities (via the indole NH), which might enhance binding affinity and potentially selectivity. Specifically, replacing the trimethoxyphenyl with a 1H-indol-3-yl group maintains the core aminopyrimidine hinge binder while exploring alternative interactions in the adjacent pocket.\",\n    \"Final_Target_Molecule\": \"Nc1nccc(-c2c[nH]c3ccccc23)n1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1cc2ncnc(NC(C)C)c2cc1OC",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, COc1cc2ncnc(NC(C)C)c2cc1OC, is a 4-aminoquinazoline derivative. It features a quinazoline heterocyclic core, substituted with two methoxy groups (-OCH3) at positions 6 and 7, and an isopropylamino group (-NHCH(CH3)2) at position 4.\",\n    \"Property_Analysis\": \"The quinazoline scaffold is common in kinase inhibitors, suggesting potential interaction with the ATP binding site of GSK3-beta. The N-isopropyl group likely occupies a hydrophobic pocket near the ATP site. The methoxy groups contribute to electron density and may influence solubility and interactions with the protein surface. However, the overall structure might lack specific interactions needed for high potency against GSK3-beta.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The primary limitation is likely the N-isopropyl group at the C4 position. While providing some hydrophobic interaction, it may not be optimal for fitting the relevant pocket in GSK3-beta. More importantly, it lacks features, such as strong hydrogen bond donors or acceptors appropriately positioned, to effectively engage with the kinase hinge region, which is crucial for potent inhibition of many kinases, including GSK3-beta.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, the C4 substituent should be modified to improve interactions, particularly with the hinge region. Replacing the N-isopropyl group with a moiety containing hydrogen bond donors/acceptors and potentially a different hydrophobic shape is a rational strategy. Introducing an anilino- or heteroarylamino- group, common in kinase inhibitors, could achieve this. Specifically, replacing the isopropylamino group with a 2-pyridylamino group introduces a nitrogen atom within the pyridine ring positioned to potentially form a hydrogen bond with the hinge region backbone residues, a well-established strategy for kinase inhibitor optimization.\",\n    \"Final_Target_Molecule\": \"COc1cc2ncnc(Nc3ncccc3)c2cc1OC\"\n  }\n]"
    },
    {
        "src_smiles": "Nc1ccnc(Nc2ccc(Oc3ccc(Cl)cc3)cc2)c1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, Nc1ccnc(Nc2ccc(Oc3ccc(Cl)cc3)cc2)c1, features a 4-aminopyridine core linked via an aniline bridge to a central phenyl ring. This central ring is further substituted with a 4-chlorophenoxy group, forming a diphenyl ether moiety.\",\n    \"Property_Analysis\": \"GSK3-beta (Glycogen Synthase Kinase 3-beta) is a serine/threonine kinase. Inhibitors typically target the ATP-binding site, often forming hydrogen bonds with the hinge region (like Val135) and occupying adjacent hydrophobic pockets. The aminopyridine core is a potential hinge binder, while the diphenyl ether moiety likely interacts with hydrophobic regions of the ATP site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 4-aminopyridine interaction with the hinge might be suboptimal. More significantly, the diphenyl ether moiety is relatively large and flexible. This flexibility can lead to an entropic penalty upon binding and may not provide an optimal fit or specific interactions within the GSK3-beta ATP binding pocket compared to more rigid or tailored substituents. The chlorine's position might not be ideal for maximizing potency.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, the flexible and potentially suboptimal diphenyl ether moiety will be replaced. A rigid heterocyclic system, such as benzimidazole, known to interact favorably in kinase active sites, will be introduced. Attaching the benzimidazole directly to the central phenyl ring aims to provide a more defined shape complementarity within the binding pocket, potentially forming additional hydrogen bonds or pi-stacking interactions, thereby increasing binding affinity.\",\n    \"Final_Target_Molecule\": \"Nc1ccnc(Nc2ccc(-c3ccc4[nH]cnc4c3)cc2)c1\"\n  }\n]"
    },
    {
        "src_smiles": "c1ccc(-c2c[nH]c(-c3ccccc3)n2)cc1",
        "prop": "gsk",
        "json_results": "[{\n  \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, 2,4-diphenyl-1H-imidazole (SMILES: c1ccc(-c2c[nH]c(-c3ccccc3)n2)cc1), features a central imidazole ring substituted with two phenyl groups at positions 2 and 4. The imidazole core contains one hydrogen bond donor (N-H) and potential hydrogen bond acceptors (imidazole nitrogens). The phenyl rings provide significant hydrophobic character.\",\n  \"Property_Analysis\": \"Imidazole derivatives are known scaffolds for various kinase inhibitors, including GSK3-beta. The planar structure and the combination of hydrophobic (phenyl rings) and hydrogen-bonding elements (imidazole NH) suggest potential binding within the ATP-binding pocket of GSK3-beta, likely through hydrophobic interactions and hydrogen bonding with hinge residues or other polar contacts.\",\n  \"Limitation_in_Source_Molecule_for_Property\": \"The unsubstituted phenyl rings might lack specific directional interactions needed for high-affinity binding to the GSK3-beta active site. The overall potency could be limited due to suboptimal interactions within the hydrophobic pockets or lack of strong hydrogen bonds with key residues like those in the hinge region.\",\n  \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, introduce substituents on one or both phenyl rings to improve binding affinity and specificity. Adding an electron-withdrawing group, such as a nitro group ([N+](=O)[O-]), at the para-position of one phenyl ring can potentially establish favorable interactions (e.g., polar or H-bond accepting) within the kinase active site, a common strategy in kinase inhibitor design. This targets the C4-phenyl ring for modification.\",\n  \"Final_Target_Molecule\": \"c1ccc(-c2c[nH]c(-c3ccc([N+](=O)[O-])cc3)n2)cc1\"\n}]"
    },
    {
        "src_smiles": "c1cnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, c1cnc(-c2c[nH]c3ncnc(N4CCOCC4)c23)cn1, features a pyrrolo[2,3-d]pyrimidine core (a 7-deazapurine analog). A morpholine ring is attached via nitrogen to the C4 position of the pyrimidine moiety. A pyrimidine ring is attached via a C-C bond to the C5 position of the pyrrole moiety. The pyrrole NH provides a hydrogen bond donor site, while various nitrogen atoms in the core and substituents act as potential hydrogen bond acceptors.\",\n    \"Property_Analysis\": \"The pyrrolo[2,3-d]pyrimidine scaffold is a known hinge-binder motif frequently found in kinase inhibitors, including those targeting GSK3-beta. The N7-H likely interacts with the kinase hinge region. The morpholine group typically occupies the solvent-exposed region, potentially influencing solubility and ADME properties. The C5-pyrimidine substituent explores a specific pocket within the ATP binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The C5-pyrimidine substituent might not provide optimal interactions (steric or electronic) within the corresponding binding pocket of GSK3-beta for high potency. Its size and specific hydrogen bonding pattern might limit affinity or selectivity. The overall interaction profile might be suboptimal for potent and selective GSK3-beta inhibition compared to other known motifs.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, the C5-substituent can be modified to enhance binding interactions. Replacing the C5-pyrimidine ring with a smaller, electronegative atom like Bromine can probe hydrophobic interactions and potentially improve shape complementarity within the binding pocket. Halogens are commonly used in kinase inhibitor optimization to fill specific pockets and enhance potency.\",\n    \"Final_Target_Molecule\": \"Brc1c[nH]c2ncnc(N3CCOCC3)c12\"\n  }\n]"
    },
    {
        "src_smiles": "CC(C)n1cnc2c(NCc3ccccc3)ncnc21",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, CC(C)n1cnc2c(NCc3ccccc3)ncnc21 (9-isopropyl-6-(benzylamino)-9H-purine), features a purine core, a common scaffold in kinase inhibitors mimicking ATP. It has an isopropyl group attached to the N9 position of the purine ring and a benzylamino group attached to the C6 position.\",\n    \"Property_Analysis\": \"The purine core likely interacts with the hinge region of GSK3-beta via hydrogen bonds. The N9-isopropyl group occupies a hydrophobic pocket near the ribose binding site. The C6-benzylamino group positions the benzyl ring in another pocket, likely hydrophobic, while the amino linker acts as a hydrogen bond donor to the hinge.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The relatively simple benzyl group might lack specific interactions needed for high potency and selectivity towards GSK3-beta compared to other kinases. The small isopropyl group might not optimally fill the N9 pocket. The overall combination may result in moderate potency or insufficient selectivity.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, modifications focused on enhancing interactions within the active site are proposed. Replace the N9-isopropyl group with a larger hydrophobic group like cyclopentyl to potentially improve pocket filling and van der Waals interactions. Replace the C6-benzyl group with a 3-pyridylmethyl group (NCc1cccnc1). The pyridine nitrogen can act as a hydrogen bond acceptor or improve polar interactions within the C6 pocket, a common feature in potent GSK3-beta inhibitors.\",\n    \"Final_Target_Molecule\": \"C1CCC(C1)n1cnc2c(NCc3cccnc3)ncnc12\"\n  }\n]"
    },
    {
        "src_smiles": "COc1ccc(SC)cc1CNC1CCCNC1c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule consists of a 4-methoxyphenyl group linked via a methylthioether (-SMe) and a methylene bridge (-CH2-) to the nitrogen atom of a 4-phenylpiperidine ring. Key fragments include: methoxy-phenyl, thioether, methylene linker, piperidine core, and phenyl substituent on piperidine.\",\n    \"Property_Analysis\": \"GSK3-beta is a kinase. Inhibitors often target the ATP binding site, typically involving hydrogen bonds with the hinge region and occupancy of hydrophobic pockets. The 4-phenylpiperidine core can occupy hydrophobic pockets, and the methoxyphenyl group might interact with other regions, but the overall structure lacks typical hinge-binding motifs common in potent kinase inhibitors.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The thioether linker (-SMe-) and the specific substitution pattern on the phenyl ring (methoxy) are not optimized for strong interactions within the ATP binding site of GSK3-beta, particularly lacking strong hydrogen bond donors/acceptors directed towards the hinge region. The overall flexibility might also hinder optimal binding conformation.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the methoxy-phenyl-thioether moiety with a group known to interact effectively with kinase hinge regions. A common strategy is to introduce a nitrogen-containing heterocycle capable of forming hydrogen bonds. Replacing 'COc1ccc(SC)cc1-' with a pyrimidinyl group linked via an amine ('pyrimidin-5-yl-NH-') introduces potential hinge-binding interactions (H-bond donor/acceptor) often crucial for kinase inhibition.\",\n    \"Final_Target_Molecule\": \"c1cncnc1NCCN1CCCNC1c1ccccc1\"\n  }\n]"
    },
    {
        "src_smiles": "c1ccc(Cn2cc(CSc3nnc(C4CCCC4)o3)nn2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, c1ccc(Cn2cc(CSc3nnc(C4CCCC4)o3)nn2)cc1, features a central 1,2,4-triazole ring. It is substituted with a benzyl group via a methylene linker at one nitrogen. The triazole is also substituted at a carbon atom with a methyl thioether linker (-CH2S-) connected to a 1,3,4-oxadiazole ring. The oxadiazole ring bears a cyclopentyl substituent.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often possess heterocyclic cores capable of hydrogen bonding within the ATP binding site, particularly the hinge region. Aromatic and hydrophobic groups typically occupy adjacent pockets. In the source molecule, the triazole and oxadiazole rings are potential hydrogen bond acceptors. The benzyl and cyclopentyl groups provide hydrophobic character. The thioether linker offers flexibility but might be prone to metabolic oxidation.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The thioether linker (-CH2S-) is a potential metabolic liability (oxidation to sulfoxide/sulfone) and lacks hydrogen bonding capability. The flexibility introduced by the multiple single bonds (benzyl-CH2-triazole, triazole-CH2-S-oxadiazole) might lead to non-optimal binding conformations. The cyclopentyl group might not be the optimal size/shape for the hydrophobic pocket interacting with GSK3-beta compared to other common hydrophobic moieties in known inhibitors.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition and improve potential metabolic stability, the thioether linker (-CH2S-) can be replaced with an amide linker (-CONH-). An amide introduces hydrogen bonding potential (donor NH, acceptor C=O) and is generally more stable metabolically than a thioether. Additionally, the cyclopentyl group can be replaced with a tert-butyl group, which is a common hydrophobic moiety found in potent GSK3-beta inhibitors known to fit well into relevant hydrophobic pockets.\",\n    \"Final_Target_Molecule\": \"O=C(Nc1nnc(C(C)(C)C)o1)c1cn(Cc2ccccc2)nn1\"\n  }\n]"
    },
    {
        "src_smiles": "Cc1cc2[nH]ncc2cc1-c1ccccc1C(F)(F)F",
        "prop": "gsk",
        "json_results": "[{\n  \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a 4-methyl-1H-pyrrolo[2,3-b]pyridine core attached via C7 to a 4-(trifluoromethyl)phenyl ring. The pyrrolo[2,3-b]pyridine is a known bioisostere of purine and often serves as a hinge-binding motif in kinase inhibitors. The methyl group is at position 4 of the pyridine ring, and the trifluoromethyl group is at the para position of the phenyl ring.\",\n  \"Property_Analysis\": \"GSK3-beta inhibition typically involves interaction with the ATP binding site. The pyrrolo[2,3-b]pyridine core is expected to form hydrogen bonds with the kinase hinge region (N-H of pyrrole and N of pyridine). The 4-(trifluoromethyl)phenyl group occupies a hydrophobic pocket, with the CF3 group contributing significantly to hydrophobic interactions and potentially influencing electronic properties.\",\n  \"Limitation_in_Source_Molecule_for_Property\": \"While the core structure provides hinge binding, the overall potency might be limited by suboptimal interactions within the hydrophobic pocket or lack of specific interactions with nearby residues. The 4-methyl group might not be optimal for steric fit or interactions. The 4-(trifluoromethyl)phenyl group, while hydrophobic, might lack features for additional specific interactions (like hydrogen bonding) that could enhance affinity and selectivity.\",\n  \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, introduce a polar group capable of forming additional hydrogen bonds while maintaining key hydrophobic interactions. Modify the 4-(trifluoromethyl)phenyl substituent by adding an amino group meta to the attachment point of the pyrrolopyridine core. This introduces a hydrogen bond donor group potentially interacting with residues or water molecules in the active site, positioned adjacent to the hydrophobic CF3 group.\",\n  \"Final_Target_Molecule\": \"Cc1cc2[nH]ncc2cc1-c1ccc(C(F)(F)F)c(N)c1\"\n}]"
    },
    {
        "src_smiles": "c1ccc2c(N3CCCCCC3)nc(-c3ccncc3)nc2c1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a quinazoline core. A phenyl ring is fused to the pyrimidine ring of the quinazoline. A pyridine ring is attached at the 2-position of the quinazoline. A large, seven-membered azepane ring is attached via its nitrogen atom to the 4-position of the quinazoline.\",\n    \"Property_Analysis\": \"Quinazoline scaffolds are common in kinase inhibitors, suggesting potential activity against GSK3-beta. The pyridine ring can act as a hinge-binding motif, interacting with the ATP-binding site. The azepane ring occupies the solvent-exposed region, influencing solubility, selectivity, and potentially interacting with residues outside the main ATP pocket.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The large and flexible azepane ring might lead to suboptimal binding affinity due to entropic penalties or poor shape complementarity within the GSK3-beta binding site. It also increases lipophilicity, potentially leading to poor pharmacokinetic properties or off-target effects. The lack of specific hydrogen bonding groups on the azepane might limit interactions.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the azepane ring at the 4-position with a smaller, potentially more conformationally restricted, and more polar heterocycle like N-methylpiperazine. This modification aims to reduce lipophilicity, improve solubility, potentially enhance binding interactions through better fit or polar contacts, and maintain or improve potency against GSK3-beta.\",\n    \"Final_Target_Molecule\": \"CN1CCN(c2nc(-c3ccncc3)nc4ccccc24)CC1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1ccc(-c2nnc(SCC#N)o2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central 1,3,4-oxadiazole ring. One side (C2) is substituted with a 4-methoxyphenyl group. The other side (C5) is substituted with a (cyanomethyl)sulfanyl group (-SCC#N). Key groups include the methoxy (-OMe), phenyl, oxadiazole, thioether (-S-), and nitrile (-C#N).\",\n    \"Property_Analysis\": \"Phenyl-oxadiazole scaffolds are recognized privileged structures in kinase inhibitor design, including GSK3-beta inhibitors. The 4-methoxyphenyl group can participate in hydrophobic interactions and potentially hydrogen bonding via the oxygen. The -(S)CH2C#N side chain can occupy a specific pocket, with the sulfur potentially interacting via hydrophobic or polar interactions and the nitrile group acting as a hydrogen bond acceptor.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The (cyanomethyl)sulfanyl (-SCC#N) side chain might not be optimal for GSK3-beta binding affinity. The thioether linkage can be metabolically liable (oxidation). The nitrile group, while a potential H-bond acceptor, might not provide the ideal geometry or interaction strength compared to other functional groups commonly found in potent GSK3-beta inhibitors (e.g., amines, amides). Potency and selectivity might be limited.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, the -(S)CH2C#N side chain was targeted for modification. It was replaced with a methylamino (-NHMe) group. This introduces a hydrogen bond donor/acceptor group common in kinase inhibitors, potentially forming stronger interactions within the ATP binding site, while removing the thioether and nitrile moieties.\",\n    \"Final_Target_Molecule\": \"COc1ccc(-c2nnc(NC)o2)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "Cn1ccc(Oc2ccc3cc(NC(=O)C4CC4)ncc3c2)n1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central quinoline core. An ether linkage connects this core to a 1-methyl-1H-imidazol-4-yl group via a phenyl ring. The quinoline core is also substituted with a cyclobutylcarboxamide group at position 6.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition typically involves interactions with the ATP-binding site, including hydrogen bonding with hinge residues (e.g., Val135) and occupation of hydrophobic pockets. Key potential interaction points in the source molecule include the amide NH (H-bond donor), amide carbonyl (H-bond acceptor), quinoline nitrogen (H-bond acceptor), and imidazole nitrogens (H-bond acceptors/donors depending on tautomeric form/protonation state, though N-methylation fixes one). The cyclobutyl and methylimidazole/phenyl groups provide hydrophobic character.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The cyclobutyl group offers limited potential for specific directional interactions (like H-bonding) and its size/shape might not be optimal for the targeted hydrophobic pocket near the amide. The overall conformation and electronic distribution might lead to suboptimal binding affinity or selectivity for GSK3-beta.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially enhance binding affinity and introduce further specific interactions, the cyclobutyl group will be replaced. An aromatic heterocycle, specifically pyridine, is chosen. Replacing the cyclobutylamide with an isonicotinamide (pyridine-4-carboxamide) introduces a nitrogen atom capable of acting as a hydrogen bond acceptor and provides a flat aromatic system which might engage in different pi-stacking or hydrophobic interactions within the binding site compared to the aliphatic cyclobutyl ring.\",\n    \"Final_Target_Molecule\": \"Cn1ccc(Oc2ccc3cc(NC(=O)c4ccncc4)ncc3c2)n1\"\n  }\n]"
    },
    {
        "src_smiles": "OCc1cccc(Nc2nc(-c3cccnc3)nc3ccccc23)c1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrimido[4,5-b]quinoline core. A pyridine ring is attached at one position of the pyrimidine ring, and an aminophenyl group is attached at another. The phenyl ring is substituted with a hydroxymethyl group (-CH2OH) at the meta position relative to the amino linker.\",\n    \"Property_Analysis\": \"The heterocyclic core contains multiple nitrogen atoms capable of forming hydrogen bonds, which are often crucial for kinase inhibition, potentially interacting with the hinge region of GSK3-beta. The aminophenyl linker positions the hydroxymethyl group in a specific region of space. The pyridine ring is a common motif in kinase inhibitors. The hydroxymethyl group can act as a hydrogen bond donor and acceptor.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The specific geometry and hydrogen bonding pattern offered by the pyrimido[4,5-b]quinoline core might not be optimal for GSK3-beta binding compared to known scaffolds. The flexibility of the aminophenyl linker and the meta-positioning of the hydroxymethyl group might lead to suboptimal interactions within the ATP binding site. The overall polarity and H-bonding capacity might need adjustment for improved potency and potentially cell permeability or selectivity.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, modifications targeting improved hydrogen bonding interactions and optimal positioning within the binding site are proposed. Replacing the meta-hydroxymethyl group (-CH2OH) with a para-sulfonamide group (-SO2NH2) is a common optimization strategy in kinase inhibitor design. The sulfonamide group offers strong hydrogen bonding potential (donor and acceptor) and the para position often directs substituents towards solvent-exposed regions or specific subpockets, potentially improving affinity and selectivity.\",\n    \"Final_Target_Molecule\": \"O=S(=O)(N)c1ccc(Nc2nc(-c3cccnc3)nc3ccccc23)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "Cn1nc(C(N)=O)c2c1-c1nc(NCc3ccccc3)ncc1CC2",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, Cn1nc(C(N)=O)c2c1-c1nc(NCc3ccccc3)ncc1CC2, features a tetracyclic fused ring system. It contains a pyrazole ring substituted with N-methyl and carboxamide groups, fused to a partially saturated cyclohexapyridine moiety, which is further fused to a pyridine ring. The pyridine ring bears a benzylamine substituent.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often interact with the ATP binding site, typically involving hinge region hydrogen bonding and occupation of hydrophobic pockets. The source molecule possesses potential hydrogen bond donors/acceptors (carboxamide NH2, amide C=O, pyrazole N, pyridine Ns, linker NH) and hydrophobic groups (benzyl ring, fused aliphatic/aromatic core). The carboxamide and pyridine nitrogens are potential hinge binders.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The primary carboxamide (C(N)=O) might not have optimal hydrogen bonding geometry or electronic properties for strong hinge interaction compared to other known motifs. The unsubstituted benzyl group may lack specific interactions within the hydrophobic pocket or could be susceptible to metabolism. The overall physicochemical properties (e.g., solubility, LogP) might not be ideal for drug-likeness or cell permeability.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially enhance GSK3-beta inhibition: 1) Replace the primary carboxamide with a group having different H-bonding properties or improved orientation, such as a cyano group (C#N), which acts as a strong H-bond acceptor but removes donor capability, altering the interaction profile. 2) Modify the benzyl group to improve hydrophobic interactions and potentially metabolic stability by adding substituents. A para-fluoro substituent (F) is introduced to the phenyl ring, a common modification to enhance binding affinity or modulate pharmacokinetics.\",\n    \"Final_Target_Molecule\": \"Cn1nc(C#N)c2c1-c1nc(NCc3ccc(F)cc3)ncc1CC2\"\n  }\n]"
    },
    {
        "src_smiles": "Cc1sc2ncnc(NCCCO)c2c1C",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a thieno[2,3-d]pyrimidine core. It is substituted with methyl groups at positions 2 and 6 of the thiophene ring and a (3-hydroxypropyl)amino group at position 4 of the pyrimidine ring.\",\n    \"Property_Analysis\": \"Thieno[2,3-d]pyrimidines can act as ATP-competitive kinase inhibitors, interacting with the hinge region via the pyrimidine nitrogens. The C4 substituent typically extends towards the solvent-exposed region or interacts with residues near the ATP site entrance, influencing potency and selectivity. The methyl groups likely occupy hydrophobic pockets.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The (3-hydroxypropyl)amino side chain at C4 might not be optimal for potent GSK3-beta inhibition. Its flexibility and the terminal hydroxyl group might not provide strong, specific interactions within the binding pocket compared to more rigid or tailored substituents often found in potent kinase inhibitors.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the flexible, hydrophilic (3-hydroxypropyl)amino group at C4 with a more rigid and potentially more interactive group, such as an aniline derivative, which is common in kinase inhibitors. Introducing a substituted phenyl ring can allow for pi-stacking interactions and probing of specific pockets. A 4-fluoroaniline group is chosen as fluorine can enhance binding affinity and improve metabolic stability.\",\n    \"Final_Target_Molecule\": \"Cc1sc2ncnc(Nc3ccc(F)cc3)c2c1C\"\n  }\n]"
    },
    {
        "src_smiles": "CCNc1nc2cc(Cl)c(C#CCCCC#N)cc2nc1NCC",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a fused pyrimido-indole-like core. It is substituted with two ethylamino groups at positions likely analogous to 2 and 4 on a pyrimidine ring, a chloro group on the indole-like portion, and a long alkynyl nitrile chain (6-cyanohex-5-yn-1-yl) also attached to the indole-like portion.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often contain heterocyclic scaffolds capable of hydrogen bonding with the kinase hinge region (likely involving the ethylamino groups and pyrimidine nitrogens). The fused ring system provides a rigid core, while substituents modulate affinity and selectivity. The long, flexible alkynyl nitrile chain likely occupies a specific pocket, potentially interacting through hydrophobic or dipole interactions, but its flexibility might be detrimental.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The long, flexible 6-cyanohex-5-yn-1-yl substituent likely incurs an entropic penalty upon binding, potentially reducing affinity. Its length and specific interactions might not be optimal for the GSK3-beta active site compared to more compact or rigid groups capable of specific hydrogen bonds or hydrophobic packing. Overall lipophilicity might also be high.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the flexible and lengthy 6-cyanohex-5-yn-1-yl group (-C#CCCCC#N) with a smaller, more rigid group known to be favorable in kinase inhibitor design, aiming to improve binding affinity and potentially physicochemical properties. Replacing it with a simple cyano group (-C#N) maintains the nitrile moiety but significantly reduces size and flexibility, potentially leading to a better fit and interaction within the binding pocket.\",\n    \"Final_Target_Molecule\": \"CCNc1nc2cc(Cl)c(C#N)cc2nc1NCC\"\n  }\n]"
    },
    {
        "src_smiles": "c1ccc(Cn2c(-c3ccccc3)nc3ccccc32)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, N-benzyl-1-phenyl-1H-benzo[d]imidazo[1,2-a]imidazole, possesses a fused heterocyclic core comprising imidazole and benzene rings. This core is substituted with a phenyl group at the C1 position of the imidazole ring and a benzyl group attached to the N2 nitrogen atom. The overall structure is largely hydrophobic due to the presence of multiple aromatic rings.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves interactions within the ATP-binding pocket, typically requiring hydrogen bonds with hinge residues (like Val135) and hydrophobic interactions. The source molecule's aromatic rings (phenyl, benzyl, benzo) can engage in hydrophobic interactions. However, the molecule lacks strong, well-positioned hydrogen bond donors or acceptors crucial for high-affinity binding to the kinase hinge region. The imidazole nitrogens could potentially act as acceptors, but their accessibility and orientation might not be optimal.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The primary limitation for potent GSK3-beta inhibition is the absence of functional groups capable of forming strong hydrogen bonds with key active site residues, particularly the kinase hinge region. The molecule relies heavily on potentially non-specific hydrophobic interactions. The bulky N-benzyl group might also cause steric hindrance or adopt non-optimal conformations within the binding site.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, introduce hydrogen bonding capabilities. A common strategy in kinase inhibitor design is adding a sulfonamide group (-SO2NH2), which provides both H-bond donor (NH2) and acceptor (O=S=O) functionalities. Placing this group on the fused benzo ring, specifically at the 7-position (para to the fusion nitrogen), directs it outwards, potentially interacting with solvent or specific residues (like Asp200/Lys85 region) without disrupting the core interactions mediated by the phenyl and core rings. This modification increases polarity and introduces targeted interactions.\",\n    \"Final_Target_Molecule\": \"O=S(=O)(N)c1ccc2c(n(Cc3ccccc3)c(-c4ccccc4)n2)c1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1ccc2nc(NC(=O)CSc3ccccc3)sc2c1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, COc1ccc2nc(NC(=O)CSc3ccccc3)sc2c1, features a 6-methoxybenzothiazole core fused system. The 2-position of the benzothiazole is substituted with an amide group, which links to a (phenylthiomethyl) moiety (benzylthiomethyl group). Key functional groups include the methoxy ether, the benzothiazole heterocycle, the secondary amide linker, the thioether, and the terminal phenyl ring.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often target the ATP-binding site. The benzothiazole scaffold is a known privileged structure for kinase inhibitors. The amide group can potentially form hydrogen bonds with the hinge region residues (like Val135). The thioether-linked phenyl group likely occupies a hydrophobic pocket. The methoxy group provides electronic influence and potential interactions.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The flexibility of the thioether linkage and the relatively featureless terminal phenyl ring might limit potency and selectivity. The phenyl group might not optimally fill the hydrophobic pocket or lack specific directional interactions (like H-bonding) often required for high affinity. The thioether sulfur might not be the optimal atom for interaction compared to oxygen or nitrogen in similar positions. The methoxy group's position and bulk might not be ideal for interactions within the specific sub-pocket of GSK3-beta.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, the terminal phenyl ring could be replaced with a heterocycle capable of forming additional hydrogen bonds or stronger polar interactions within the binding site. Replacing the phenyl ring with a pyridine ring, specifically 4-pyridyl, introduces a nitrogen atom as a potential hydrogen bond acceptor, which could interact favorably with residues in the GSK3-beta active site while maintaining aromatic interactions.\",\n    \"Final_Target_Molecule\": \"COc1ccc2nc(NC(=O)CSc3ccncc3)sc2c1\"\n  }\n]"
    },
    {
        "src_smiles": "c1ccc(-c2nc(-c3ccccc3)c(-c3ccccc3)[nH]2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule is 2,4,5-triphenyl-1H-imidazole. It features a central imidazole core substituted with three phenyl rings at positions 2, 4, and 5. The imidazole ring contains an NH group capable of acting as a hydrogen bond donor.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves interactions within the ATP-binding site, requiring specific hydrogen bonds with hinge residues (like Val135) and hydrophobic interactions. The imidazole scaffold is present in known kinase inhibitors, but the triphenyl substitution pattern might not be optimal for GSK3-beta.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The molecule lacks strong, strategically positioned hydrogen bond acceptors to interact effectively with the GSK3-beta hinge region. The symmetry and bulk of the three phenyl rings may hinder optimal fitting and specific interactions within the ATP pocket. Unsubstituted phenyl rings can also be metabolically labile.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, introduce a hydrogen bond acceptor group oriented towards the hinge region. Replacing the phenyl ring at the 2-position with a pyridine ring (specifically, pyridin-3-yl or pyridin-4-yl) can provide a nitrogen atom positioned for potential hinge binding, a common strategy in kinase inhibitor design.\",\n    \"Final_Target_Molecule\": \"c1ccc(cc1)c1c(-c2ccccc2)nc(-c2cnccc2)[nH]1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1n[nH]c2cc(NC(=O)NC(C)c3ccc(F)cc3)ncc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a 7-methoxy-1H-pyrazolo[3,4-b]pyridine core. Attached to the C5 position of the pyridine ring is a urea linker (`-NH-C(=O)-NH-`). This linker connects the core to a chiral side chain, specifically (1-(4-fluorophenyl)ethyl). Key functional groups include the methoxy ether, the pyrazolopyridine heterocycle, the urea group (H-bond donor/acceptor), the chiral center, and the p-fluorophenyl ring.\",\n    \"Property_Analysis\": \"GSK3-beta is a kinase. Inhibitors typically bind in the ATP pocket. The pyrazolo[3,4-b]pyridine core can act as a hinge-binding scaffold. The urea group is crucial for forming hydrogen bonds with the hinge region residues (like Val135 backbone). The p-fluorophenyl group likely occupies a hydrophobic pocket within the ATP binding site, with the fluorine potentially influencing binding affinity and metabolic stability. The chiral center suggests stereospecific binding interactions.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 7-methoxy group might not be optimal for potency or could introduce metabolic liability (O-demethylation). While the core and urea are common motifs, their specific arrangement and substituents might offer only moderate affinity or selectivity against other kinases. The p-fluorophenyl group might not fully exploit the hydrophobic pocket compared to alternative substituents.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve potency and metabolic stability while maintaining key interactions, the 7-methoxy group can be removed. This modification simplifies the molecule and eliminates a potential site of metabolism (O-demethylation). Replacing -OCH3 with -H probes the necessity of a substituent at this position for GSK3-beta inhibition, focusing optimization on the core scaffold interaction.\",\n    \"Final_Target_Molecule\": \"c1n[nH]c2cc(NC(=O)NC(C)c3ccc(F)cc3)ncc12\"\n  }\n]"
    },
    {
        "src_smiles": "COc1ccc(C(=O)OCC(=O)NCc2ccco2)cc1OC",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, SMILES: COc1ccc(C(=O)OCC(=O)NCc2ccco2)cc1OC, features a central ester linkage connecting a dimethoxybenzoyl moiety to an N-furfurylglycinate fragment. Key functional groups include two methoxy ethers on a benzene ring, an ester group, an amide group, and a furan ring.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition typically involves interactions within the ATP-binding site, often requiring hydrogen bond donors and acceptors, and specific heterocyclic systems to interact with the hinge region (e.g., Asp133, Val135) and other key residues. The source molecule possesses potential hydrogen bond acceptors (ether oxygens, ester carbonyl oxygen, ester ether oxygen, amide carbonyl oxygen, furan oxygen) and one hydrogen bond donor (amide N-H). The furan ring provides a heterocyclic element.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The furan ring may not be optimal for strong interactions within the GSK3-beta active site compared to other heterocycles frequently found in kinase inhibitors (like thiazole, pyridine, pyrimidine). The ester linkage is potentially susceptible to hydrolysis by esterases, leading to metabolic instability. The overall flexibility and arrangement of functional groups might not lead to an optimal binding pose for potent inhibition.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, the furan ring is replaced with a thiazole ring. Thiazole rings are common scaffolds in known GSK3-beta inhibitors (e.g., AR-A014418 analogues). The nitrogen atom in the thiazole ring can act as a hydrogen bond acceptor, potentially forming a crucial interaction with the hinge region of the kinase active site, mimicking the role of the adenine nitrogen in ATP. This modification retains the core structure while substituting a key pharmacophoric element for better target engagement.\",\n    \"Final_Target_Molecule\": \"COc1ccc(C(=O)OCC(=O)NCc2nccs2)cc1OC\"\n  }\n]"
    },
    {
        "src_smiles": "O=C1NC(=O)C(=Cc2ccc(O)cc2)N1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, O=C1NC(=O)C(=Cc2ccc(O)cc2)N1, is 5-(4-hydroxybenzylidene)barbituric acid. It features a barbituric acid core, which acts as a potential hydrogen bond donor (NH) and acceptor (C=O). This core is substituted at the 5-position with a benzylidene moiety containing a para-hydroxyl group, capable of hydrogen bonding.\",\n    \"Property_Analysis\": \"GSK3-beta is a serine/threonine kinase. Inhibition typically involves interactions within the ATP-binding site, including hydrogen bonds with the hinge region (e.g., Val135 N-H) and occupation of hydrophobic pockets. The barbituric acid core can potentially form hinge interactions, while the substituted phenyl ring occupies a hydrophobic pocket. The para-hydroxy group could interact with specific residues or water molecules.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The potency of simple benzylidenebarbiturates against GSK3-beta might be limited. The barbituric acid core may not be optimal for achieving high affinity or selectivity compared to scaffolds like maleimides or indirubins often found in potent GSK3-beta inhibitors. The single para-hydroxy substitution might not fully exploit the available interactions within the binding pocket for optimal potency and selectivity.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, we can modify the benzylidene substituent to improve interactions within the ATP binding site. Introducing a halogen atom, such as chlorine, ortho to the hydroxyl group can potentially increase hydrophobic interactions, modulate the electronic properties of the phenyl ring, and possibly induce a conformational preference that favors binding. This modification aims to improve occupancy of the hydrophobic pocket adjacent to the hinge region.\",\n    \"Final_Target_Molecule\": \"O=C1NC(=O)C(=Cc2ccc(O)c(Cl)c2)N1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(CO)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features an imidazo[1,2-a]pyridine core. Attached to the pyridine nitrogen (position 1) via an ether linkage is a (1-hydroxypropan-2-yl)oxy group (CC(CO)CO-). Attached at position 6 of the imidazopyridine core is a urea linker (-NC(=O)NH-) substituted with a chiral (1-phenylethyl) group (-(C(C)c1ccccc1)).\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often engage the hinge region via hydrogen bonding, typically involving groups like the urea moiety. The hydrophobic pocket is usually occupied by aryl or heteroaryl groups, like the phenylethyl group here. The imidazopyridine scaffold is known in kinase inhibition. The side chain attached to the core influences solubility and can make secondary interactions.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The (1-hydroxypropan-2-yl)oxy side chain might be suboptimal for potency or could introduce metabolic liabilities (e.g., glucuronidation). The unsubstituted phenyl ring in the urea substituent might lack specific interactions or desired electronic properties for optimal GSK3-beta inhibition compared to substituted or heteroaromatic rings.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially enhance GSK3-beta inhibition: 1. Replace the phenyl ring of the urea substituent with a pyridine ring, specifically pyridine-3-yl, which is found in potent GSK3 inhibitors and can offer improved interactions (H-bonding potential) and properties. 2. Simplify the side chain on the imidazopyridine core to a simple methyl group to reduce complexity and potentially improve metabolic stability or hydrophobic interactions, assuming the complex alcohol is not crucial for binding.\",\n    \"Final_Target_Molecule\": \"Cc1n[nH]c2cc(NC(=O)NC(C)c3cccnc3)ncc12\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrazolo[1,5-a]pyrimidine core linked via an urea group to a chiral 1-phenylethyl moiety. Position 3 of the pyrazole ring is substituted with a benzyloxy group.\",\n    \"Property_Analysis\": \"Pyrazolo[1,5-a]pyrimidines are known scaffolds for kinase inhibitors. The urea linker can form hydrogen bonds common in kinase active sites. The terminal phenyl rings (from phenylethyl and benzyloxy) likely occupy hydrophobic pockets within the GSK3-beta active site. The nitrogen atoms in the core can act as hydrogen bond acceptors, potentially interacting with the hinge region.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The benzyloxy group is relatively large, flexible, and lipophilic, which might lead to suboptimal interactions, potential metabolic liabilities (O-dealkylation), or poor solubility. The flexibility of the ether linkage might reduce binding affinity compared to a more rigid substituent.\",\n    \"Optimization_for_Source_Molecule\": \"To improve binding affinity and potentially metabolic stability, the flexible and bulky benzyloxy group can be replaced. Replacing the -OCc3ccccc3 group with a directly attached phenyl group (-c3ccccc3) removes the flexible ether linker, potentially improving rigidity and optimizing interactions within the hydrophobic pocket. This modification retains aromatic interactions while altering the geometry and removing a potential metabolic site.\",\n    \"Final_Target_Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(c3ccccc3)c2cn1)c1ccccc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(c1ccncc1)c1nnc(Nc2ccc(Cl)cc2)c2ccccc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central triazolobenzodiazepine core. Attached to the benzodiazepine ring is a chiral center bearing a methyl group and a pyridine ring. The triazole ring is substituted with an aniline moiety, specifically 4-chloroaniline.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often interact with the ATP binding site. Key interactions typically involve hydrogen bonding with the hinge region (e.g., Val135) and hydrophobic interactions. The pyridine nitrogen and the aniline NH can act as H-bond acceptors/donors. The chloroaniline and the fused rings likely occupy hydrophobic pockets. The chiral center suggests stereospecific binding.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The pyridine ring, while capable of H-bonding, might not be optimally positioned or electronically suited for strong interaction with the hinge region compared to other heterocycles frequently found in potent kinase inhibitors. The overall potency might be moderate, and there could be room for enhancing interactions within the ATP pocket.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the pyridine ring with a pyrimidine ring. Pyrimidines are common scaffolds in kinase inhibitors and offer two nitrogen atoms as potential hydrogen bond acceptors, potentially allowing for stronger or alternative interactions with the hinge region or other residues in the GSK3-beta active site. This modification retains the core structure and the chloroaniline substituent while exploring improved interactions via the heterocyclic appendage.\",\n    \"Final_Target_Molecule\": \"CC(c1cncnc1)c1nnc(Nc2ccc(Cl)cc2)c2ccccc12\"\n  }\n]"
    },
    {
        "src_smiles": "CCC(O)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrazolo[3,4-b]pyridine core. Attached to the pyrazole nitrogen (N1) is a (2-hydroxy)butoxy group (CCC(O)CO-). Attached to the pyridine ring (C4) is a urea-linked chiral alpha-methylbenzyl group (-NHC(=O)NHC(C)c1ccccc1). Key features include the heterocyclic core, hydrogen bond donors/acceptors (pyrazole NH, urea NHs, alcohol OH, pyridine N), a chiral center in the butoxy side chain, and a chiral center in the urea side chain, along with hydrophobic groups (ethyl, phenyl).\",\n    \"Property_Analysis\": \"GSK3-beta is a serine/threonine kinase. Inhibitors typically bind to the ATP-binding site. Effective inhibition often involves hydrogen bonding interactions with the kinase hinge region and hydrophobic/van der Waals interactions within the pocket. The source molecule possesses a scaffold (pyrazolopyridine) known to interact with kinases, hydrogen bond donors/acceptors (urea, pyrazole NH, alcohol OH) potentially interacting with the hinge or solvent, and hydrophobic groups (phenyl, ethyl) for pocket interactions.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The existing urea linker, while providing H-bond donors, might not have optimal geometry or electronic properties for strong hinge binding compared to other motifs (e.g., amides). The phenyl group in the side chain might not optimally fill the hydrophobic pocket or could be replaced by groups offering additional interactions (e.g., polar contacts). The flexibility and specific conformation of the (2-hydroxy)butoxy side chain might not be ideal for binding or could introduce metabolic liabilities via the secondary alcohol.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, focus on optimizing interactions within the ATP binding site. Strategy: Modify the urea-linked side chain. Replace the urea linkage (-NHC(=O)NH-) with an amide linkage (-NHC(=O)-) to potentially improve binding geometry or metabolic stability. Replace the terminal phenyl group with a 3-pyridyl group to explore potential hydrogen bonding with residues in the pocket or improved polar interactions while maintaining an aromatic hydrophobic component. The chiral center adjacent to the aromatic ring is retained. The (2-hydroxy)butoxy side chain is kept unchanged in this specific optimization step.\",\n    \"Final_Target_Molecule\": \"CCC(O)COc1n[nH]c2cc(NC(=O)C(C)c3ncccc3)ncc12\"\n  }\n]"
    },
    {
        "src_smiles": "COc1ccccc1-c1ccc(CC(NC(=O)Cn2cnnn2)C(=O)O)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a biphenyl scaffold. One phenyl ring is para-substituted with a methoxy group. The other phenyl ring is para-substituted with a 2-(acylamino)-propanoic acid derivative. The acyl group is derived from (1H-tetrazol-1-yl)acetic acid (assuming the standard isomer for Cn2cnnn2 is C-N1=NN=CN1 or C-N1N=NC=N1, interpreted here as 1H-tetrazol-1-yl-methyl). Key functional groups include: ether (methoxy), biphenyl core, chiral alpha-carbon, secondary amide, carboxylic acid, and a tetrazole ring.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves interactions with the ATP binding site, including hydrogen bonding with hinge residues (e.g., Val135) and occupation of hydrophobic pockets. The source molecule possesses potential hydrogen bond donors (NH, OH) and acceptors (C=O, -O-, tetrazole nitrogens, ether oxygen). The biphenyl core provides hydrophobicity. The carboxylic acid can form salt bridges or H-bonds. The tetrazole acts as a potential H-bond acceptor.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The biphenyl core might confer excessive flexibility or non-optimal geometry for the GSK3-beta active site. The specific side chain `CC(NC(=O)Cn2cnnn2)C(=O)O` might not present the ideal interactions; the tetrazolylmethyl group attached to the amide nitrogen is relatively complex and its contribution to binding is uncertain compared to established GSK3-beta pharmacophores. The overall lipophilicity and polarity balance might need adjustment for optimal potency and ADME properties.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, the complex tetrazolylmethyl group on the amide nitrogen will be replaced. Substituting it with a simple phenyl ring aims to explore potentially beneficial hydrophobic interactions within the binding site, simplify the structure, and modify the electronic properties of the amide group. This maintains the core amino acid and biphenyl scaffold while probing a different substituent interaction profile.\",\n    \"Final_Target_Molecule\": \"COc1ccccc1-c1ccc(CC(NC(=O)c2ccccc2)C(=O)O)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "Brc1cnc(N2CCOCC2)nc1Nc1cc(C2CC2)[nH]n1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central 2,4-substituted pyrimidine ring. Position 2 is substituted with an amino group linking to a 5-cyclopropyl-1H-pyrazol-3-amine moiety. Position 4 is substituted with a morpholino group. Position 5 of the pyrimidine ring bears a bromine atom.\",\n    \"Property_Analysis\": \"The molecule possesses typical features of kinase inhibitors, including hydrogen bond donors/acceptors (amino linker, pyrazole NH, pyrimidine nitrogens, morpholine oxygen/nitrogen) likely interacting with the GSK3-beta hinge region and ATP-binding site. The morpholine group enhances solubility, while the cyclopropyl group likely occupies a hydrophobic pocket. The bromine atom contributes to lipophilicity and potentially specific interactions within the binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The bromine atom at position 5 of the pyrimidine ring might not be optimal for potency or selectivity. It could introduce steric hindrance, unfavorable electronic effects, or potential metabolic liabilities compared to other substituents. The overall combination of substituents might not achieve maximal binding affinity within the GSK3-beta active site.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the bromine atom on the pyrimidine ring with a fluorine atom. Fluorine is smaller than bromine, potentially reducing steric clash and allowing better fit. Its high electronegativity can modulate electronic properties and potentially form favorable interactions (like halogen bonds or dipole interactions) within the active site, often leading to improved potency and metabolic stability compared to bromine.\",\n    \"Final_Target_Molecule\": \"Fc1cnc(N2CCOCC2)nc1Nc1cc(C2CC2)[nH]n1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccc3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrazolo[1,5-a]pyrimidine core linked via a urea group to a chiral (1-phenylethyl)amine moiety. The pyrazole ring is substituted with a benzyloxy group.\",\n    \"Property_Analysis\": \"The pyrazolo[1,5-a]pyrimidine scaffold is a known hinge-binding motif for various kinases, including GSK3-beta. The urea linker can form hydrogen bonds within the ATP binding site. The benzyloxy group likely occupies a hydrophobic pocket, and the chiral amine interacts with another region of the binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The benzyloxy group, while occupying a pocket, might not be optimal in size, flexibility, or electronic properties for maximum affinity and selectivity towards GSK3-beta. Its flexibility might incur an entropic penalty upon binding. The phenyl ring could also be a site for metabolic oxidation.\",\n    \"Optimization_for_Source_Molecule\": \"To improve affinity and potentially metabolic stability, the benzyloxy group can be replaced. A smaller, less flexible hydrophobic group like a methyl group could be explored to maintain interaction within the pocket while potentially improving the binding kinetics or thermodynamics and reducing metabolic liabilities associated with the benzyl ether.\",\n    \"Final_Target_Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(C)c2cn1)c1ccccc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(CCn1ccc(-c2ccc(F)cc2)cc1=O)(C(=O)NO)S(C)(=O)=O",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyridone core linked via an ethyl chain (bearing a quaternary carbon) to a fluorophenyl group. The quaternary carbon is substituted with a methyl group, a hydroxamic acid moiety (C(=O)NO), and a methylsulfonyl group (S(C)(=O)=O). Key features include the pyridone ring, the fluorophenyl group, the linker chain, and the highly substituted quaternary center with polar functional groups (hydroxamic acid, sulfone).\",\n    \"Property_Analysis\": \"The fluorophenyl-pyridone core is a common scaffold in kinase inhibitors, potentially interacting with the hinge region and hydrophobic pockets of GSK3-beta. The hydroxamic acid group is a strong hydrogen bond donor/acceptor and metal chelator, though less typical for serine/threonine kinase inhibitors compared to metalloenzyme inhibitors. The methylsulfonyl group adds polarity and hydrogen bonding capacity. The quaternary center introduces steric bulk.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The hydroxamic acid group (C(=O)NO) is often associated with poor pharmacokinetic properties (metabolic instability, potential toxicity) and may not be optimal for GSK3-beta binding compared to typical kinase inhibitor functional groups. The combined bulk and polarity of the hydroxamic acid and methylsulfonyl groups on the quaternary center might lead to suboptimal steric and electronic interactions within the GSK3-beta active site. The complexity of this side chain could hinder optimal binding and potentially reduce cell permeability or increase metabolic liabilities.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition and potentially enhance drug-like properties, the complex and potentially problematic side chain containing the hydroxamic acid and methylsulfonyl groups will be simplified. We will remove the quaternary center and its substituents (methyl, hydroxamic acid, methylsulfonyl) and replace the entire branched ethyl linker `CC(C(C(=O)NO)S(C)(=O)=O)C` connected to the nitrogen with a simple n-propyl group `CCC`. This simplification retains the core fluorophenyl-pyridone scaffold but removes the complex, potentially unfavorable side chain, aiming for improved binding affinity and pharmacokinetic profile.\",\n    \"Final_Target_Molecule\": \"CCCn1ccc(-c2ccc(F)cc2)cc1=O\"\n  }\n]"
    },
    {
        "src_smiles": "COCCSc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a 1H-pyrazolo[3,4-b]pyridine core. A (methoxymethyl)sulfanyl group (COCCSc-) is attached at the C3 position of the pyrazole ring. An N-(1-phenylethyl)urea moiety (-NHC(=O)NHCH(C)c1ccccc1) is attached to the C5 position of the pyridine ring. Key features include the heterocyclic core, the urea linker capable of H-bonding, the chiral phenylethyl group, and the thioether substituent.\",\n    \"Property_Analysis\": \"The pyrazolo[3,4-b]pyridine scaffold is a known hinge-binding motif for various kinases, including GSK3-beta. The urea group typically forms crucial hydrogen bonds with the kinase hinge region backbone. The N-(1-phenylethyl) group likely occupies a hydrophobic pocket adjacent to the ATP binding site. The (methoxymethyl)sulfanyl group at C3 interacts with another region of the active site, potentially influencing potency and selectivity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The (methoxymethyl)sulfanyl group at C3 might not be optimal for GSK3-beta inhibition. This group can be metabolically labile (e.g., oxidation at sulfur) and may not provide ideal steric or electronic interactions within its sub-pocket. Its flexibility might also be unfavorable entropically. Optimizing this position could lead to improved potency, selectivity, or pharmacokinetic properties.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the potentially suboptimal (methoxymethyl)sulfanyl group (-SCC(OC)C) at the C3 position with a cyclopropyl group. Cyclopropyl groups are often used in kinase inhibitors to fill small hydrophobic pockets, enhance metabolic stability compared to thioethers, and potentially improve binding affinity due to favorable conformational rigidity and lipophilicity.\",\n    \"Final_Target_Molecule\": \"C3CC3c1n[nH]c2cc(NC(=O)NC(C)c4ccccc4)ncc12\"\n  }\n]"
    },
    {
        "src_smiles": "COCCOc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features an imidazo[4,5-b]pyridine core. Attached to position 6 of the pyridine ring is a 2-methoxyethoxy group (COCCO). Position 5 of the fused system (position 2 of the imidazole ring) is substituted with an amino group, which forms a urea linkage (NC(=O)N) with a chiral (1-phenylethyl) moiety (C(C)c3ccccc3).\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves interactions within the ATP binding site. The imidazo[4,5-b]pyridine core and the urea group are potential hinge binders via hydrogen bonds. The N-H of the imidazole and the pyridine nitrogen can act as H-bond acceptors/donors. The urea oxygens and nitrogens provide additional H-bonding capabilities. The (1-phenylethyl) group likely occupies a hydrophobic pocket.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 2-methoxyethoxy group (COCCO) at position 6 might not be optimal for potency or pharmacokinetic properties. Its flexibility could be entropically unfavorable for binding, and it might be metabolically liable. The unsubstituted phenyl ring offers limited scope for specific interactions within its binding pocket.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve potency and metabolic stability, the flexible and potentially labile 2-methoxyethoxy group at position 6 can be replaced. A common optimization strategy is to substitute such groups with halogens or small, rigid substituents. Replacing it with a Chlorine (Cl) atom is a reasonable starting point, as halogens often enhance binding affinity through hydrophobic or specific halogen-bonding interactions and can improve metabolic stability.\",\n    \"Final_Target_Molecule\": \"Clc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrazolo[1,5-a]pyrimidine core, known to interact with kinase hinge regions. This core is linked via a urea moiety to a chiral (1-phenylethyl)amino group. The pyrazole ring is substituted at the 3-position with a (difluoroethylaminomethyl) side chain.\",\n    \"Property_Analysis\": \"The pyrazolo[1,5-a]pyrimidine core acts as a hinge binder for GSK3-beta. The urea linker provides hydrogen bonding opportunities within the active site. The chiral phenylethyl group likely occupies a hydrophobic pocket, and the difluoroethylaminomethyl side chain extends towards the solvent-exposed region, influencing potency and potentially physicochemical properties.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The unsubstituted phenyl ring might offer suboptimal hydrophobic interactions. The difluoroethyl group, while potentially increasing metabolic stability, might not provide optimal interactions in the solvent-exposed region and could negatively impact permeability or solubility. The overall combination might not achieve maximum potency or desired selectivity for GSK3-beta.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition and potentially improve properties, we propose two modifications: 1) Introduce a para-fluoro substituent on the phenyl ring to probe halogen bonding or improve hydrophobic interactions and metabolic stability. 2) Replace the difluoroethylaminomethyl side chain with a morpholinomethyl group, which is frequently observed in potent kinase inhibitors to improve potency and pharmacokinetic properties by interacting favorably in the solvent-exposed region.\",\n    \"Final_Target_Molecule\": \"CC(c1ccc(F)cc1)NC(=O)Nc1cc2[nH]nc(CN3CCOCC3)c2cn1\"\n  }\n]"
    },
    {
        "src_smiles": "CCCNC(=O)N1C(C#N)C(c2ccc(C3=CCCCC3)cc2)C1CO",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrrolidine core. Key substituents include an N-propylurea attached to the pyrrolidine nitrogen, a cyano group and a hydroxymethyl group attached to adjacent carbons on the pyrrolidine ring, and a 4-(cyclohex-1-en-1-yl)phenyl group attached to another carbon of the pyrrolidine ring. The molecule possesses multiple chiral centers on the pyrrolidine ring.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often interact with the ATP binding site. The urea motif (-NHC(=O)N-) is a common feature in kinase inhibitors, capable of forming hydrogen bonds with the hinge region residues. The 4-(cyclohex-1-en-1-yl)phenyl group likely occupies a hydrophobic pocket. The cyano and hydroxymethyl groups might engage in specific interactions or influence physicochemical properties.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The N-propyl group on the urea might offer suboptimal hydrophobic interactions or lack specific interactions compared to more structured groups. The flexibility and specific shape of the cyclohexenylphenyl moiety might not be ideal for maximizing interactions within the GSK3-beta binding site. The overall potency might be limited by the specific combination and spatial arrangement of these substituents.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially enhance GSK3-beta inhibition, replace the N-propyl group with a moiety capable of stronger or more specific interactions. Replacing the propyl group with an aromatic heterocycle, such as pyridine, could introduce favorable pi-stacking interactions or additional hydrogen bonding opportunities with the kinase, potentially improving binding affinity. Specifically, replacing N-propyl with N-(pyridin-2-yl) maintains the urea H-bond donor capability while adding an aromatic system.\",\n    \"Final_Target_Molecule\": \"O=C(Nc1ccccn1)N1C(C#N)C(c2ccc(C3=CCCCC3)cc2)C1CO\"\n  }\n]"
    },
    {
        "src_smiles": "Cc1cc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)cc(C)n1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central 1,3-disubstituted pyrazole ring linked to a 2,6-dimethylpyridine moiety at its 5-position and a 4-fluorophenyl group at its 3-position. The pyrazole N1 position is substituted with a propyl chain connected to a terminal morpholine ring.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often possess heterocyclic cores (like pyridine and pyrazole) that can interact with the kinase hinge region via hydrogen bonds. The 4-fluorophenyl group likely occupies a hydrophobic pocket, and the morpholine group interacts with the solvent-exposed region. The linker length influences the positioning of the morpholine group.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The morpholine oxygen provides limited hydrogen bonding capability compared to amine groups. The overall lipophilicity might be high. The interaction of the 4-fluorophenyl and dimethylpyridine groups with their respective pockets may not be optimal for maximizing potency.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially enhance interactions in the solvent-exposed region and explore additional hydrogen bonding opportunities or points for further functionalization, the terminal morpholine ring can be replaced with a piperazine ring. Piperazine retains similar size and polarity characteristics but offers an additional basic nitrogen atom.\",\n    \"Final_Target_Molecule\": \"Cc1cc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCNCC2)cc(C)n1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1c(N2CCCC(N)C2)c(F)c(N)c2c(=O)c(C(=O)O)cn(C3CC3)c12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule is a complex fluoroquinolone derivative featuring a 1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid core. Key substituents include a methoxy group at C8, a 3-aminopyrrolidin-1-yl group at C7, a fluorine atom at C6, and an amino group at C5.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves ATP-competitive binding within the kinase hinge region. The quinolone core can potentially mimic the adenine scaffold of ATP. The carboxylic acid at C3 might interact with key residues like Lys85. The substituents at C5, C7, and C8 occupy regions surrounding the ATP pocket and significantly influence potency and selectivity. The 3-aminopyrrolidine at C7 introduces basicity and hydrogen bonding potential, while the C5 amino group adds further polarity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The large and basic 3-aminopyrrolidine group at C7, along with the C5 amino group, might lead to suboptimal binding affinity or poor selectivity for GSK3-beta versus other kinases or targets (like bacterial gyrase, given the fluoroquinolone scaffold). The primary amine on the pyrrolidine could also introduce metabolic liabilities or unfavorable physicochemical properties. The overall polarity might be too high.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, simplify the C7 substituent and reduce basicity/polarity. Replace the complex 3-aminopyrrolidin-1-yl group (N2CCCC(N)C2) with a simpler amino group (N). Additionally, remove the C5 amino group (N) and replace it with hydrogen (H) to reduce polarity and potential steric hindrance. These changes aim to optimize interactions within the GSK3-beta active site while potentially improving selectivity and drug-like properties.\",\n    \"Final_Target_Molecule\": \"COc1c(N)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12\"\n  }\n]"
    },
    {
        "src_smiles": "CC1CN(c2c(F)c(N)c3c(=O)c(C(=O)O)cn(C4CC4)c3c2F)C(C)CN1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule is a fluoroquinolone derivative featuring a 4-quinolone-3-carboxylic acid core. Key substituents include an N1-cyclopropyl group, a C7-(3,5-dimethylpiperazin-1-yl) group, a C5-amino group, and fluoro groups at C6 and C8 positions.\",\n    \"Property_Analysis\": \"The fluoroquinolone core, particularly the planar ring system and carboxylic acid, can potentially interact with the ATP-binding site of GSK3-beta, mimicking interactions of known inhibitors. The N1-cyclopropyl and C7-piperazine substituents significantly modulate potency, selectivity, and pharmacokinetic properties. Fluorine atoms influence electronic properties and binding affinity. The C5-amino group can act as a hydrogen bond donor.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The bulky and relatively flexible 3,5-dimethylpiperazine substituent at the C7 position might not fit optimally into the GSK3-beta active site or could lead to an entropic penalty upon binding. The quinolone core itself might confer undesirable off-target effects (e.g., antibacterial activity, phototoxicity) or suboptimal ADME properties for a GSK3-beta inhibitor profile. The specific substitution pattern (C5-NH2, C6-F, C8-F) might not be ideal for maximizing interactions within the GSK3-beta ATP pocket compared to established GSK3-beta pharmacophores.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, the C7 substituent is targeted for modification, as it is a common site for tuning kinase inhibitor properties. Replacing the relatively large and flexible 3,5-dimethylpiperazine ring with a smaller, less flexible pyrrolidine ring (Pyrrolidin-1-yl) aims to improve binding affinity and potentially reduce steric clashes within the active site, while retaining a basic nitrogen atom often favorable for kinase interactions.\",\n    \"Final_Target_Molecule\": \"O=C(O)c1cn(C2CC2)c3c(F)c(N4CCCC4)c(F)c(N)c3c1=O\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCc3cncs3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a chiral (R/S)-1-phenylethylamine moiety linked via a urea group to an imidazo[4,5-c]pyridine core. This core is further substituted with a (thiazol-2-ylmethoxy) group.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often contain heterocyclic cores capable of hinge binding (like imidazopyridine) and urea linkers for hydrogen bonding. The terminal thiazole and phenylethyl groups occupy different pockets, influencing potency and selectivity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The thiazole ring might not provide optimal interactions within the corresponding GSK3-beta binding pocket compared to other heterocycles. Its size, shape, and electronic properties might limit potency or introduce unfavorable interactions.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the terminal thiazole ring with a pyridine ring. Pyridine is frequently found in kinase inhibitors and can offer different hydrogen bonding patterns (nitrogen as acceptor) and potentially improved pi-stacking interactions or shape complementarity within the target pocket, potentially enhancing GSK3-beta inhibition.\",\n    \"Final_Target_Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(OCc3ccccn3)c2cn1)c1ccccc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(S(C)(=O)=O)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a chiral (1-phenylethyl) moiety linked via a urea group (-NHC(=O)NH-) to an imidazo[1,2-b]pyridazine heterocyclic core. The imidazo[1,2-b]pyridazine core is substituted with a methyl sulfonyl group (-S(C)(=O)=O) at position 6.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often possess heterocyclic scaffolds that interact with the ATP binding site. The urea linker commonly forms hydrogen bonds with the hinge region residues. The methyl sulfonyl group acts as a potential hydrogen bond acceptor and occupies a specific sub-pocket. The (1-phenylethyl) group explores another pocket, and its chirality is usually critical for potency.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The methyl sulfonyl group, while a potential H-bond acceptor, might introduce excessive bulk or unfavorable electronic properties for optimal interaction within the GSK3-beta active site sub-pocket it occupies. Its size and orientation might not be ideal for maximizing binding affinity compared to other potential substituents.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve binding affinity, the methyl sulfonyl group (-S(C)(=O)=O) can be replaced with a smaller, polar group known to interact favorably in kinase active sites, such as a cyano group (-C#N). A cyano group is smaller, planar, and a good hydrogen bond acceptor, potentially leading to a better fit and stronger interactions within the targeted sub-pocket.\",\n    \"Final_Target_Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(C#N)c2cn1)c1ccccc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(C)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrido[2,3-d]pyrimidin-7-one core. Key substituents include an isopropylamino group at the C2 position of the pyrimidine ring, a 2,6-dichlorophenyl group at the C5 position of the pyridone ring, and a methyl group on the N8 nitrogen of the pyridone ring.\",\n    \"Property_Analysis\": \"The pyrido[2,3-d]pyrimidin-7-one scaffold is a known hinge-binding motif for various kinases, including GSK3-beta. The dichlorophenyl group likely occupies the hydrophobic pocket within the ATP binding site, while the isopropylamino group might interact with the solvent-exposed region or contribute to hinge interactions. The N-methyl group influences solubility and potentially interactions within the binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 2,6-dichlorophenyl group, while providing hydrophobic interactions, lacks specific hydrogen bonding potential with the hinge region residues typically crucial for high GSK3-beta potency and selectivity. Its bulk and hydrophobicity might also negatively impact solubility and ADMET properties. The isopropylamino group might not be optimal for maximizing potency or selectivity compared to other potential substituents.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, the 2,6-dichlorophenyl group at C5 can be replaced with a heteroaromatic ring capable of forming a hydrogen bond with the kinase hinge region backbone NH. A 4-pyridyl group is a common and effective replacement in GSK3-beta inhibitors for this purpose, as the pyridine nitrogen can act as a hydrogen bond acceptor. Other substituents (isopropylamino at C2, N-methyl at N8) are retained initially to isolate the effect of the C5 modification.\",\n    \"Final_Target_Molecule\": \"CC(C)Nc1ncc2cc(-c3ccncc3)c(=O)n(C)c2n1\"\n  }\n]"
    },
    {
        "src_smiles": "Cn1c(-c2ccnc(Oc3ccccc3)n2)c(-c2ccc(F)cc2)c(=O)n1C",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central 1,3-dimethylpyrimidine-2,4(1H,3H)-dione core. It is substituted at position 5 with a 4-fluorophenyl group and at position 6 with a 4-(phenoxy)pyrimidin-2-yl group.\",\n    \"Property_Analysis\": \"Pyrimidine-dione scaffolds are known privileged structures for kinase inhibition, including GSK3-beta. The 4-fluorophenyl group likely occupies a hydrophobic pocket, potentially interacting near the hinge region. The 4-(phenoxy)pyrimidin-2-yl group is larger and likely extends towards the solvent-exposed region or interacts with other subpockets within the ATP binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 4-(phenoxy)pyrimidin-2-yl substituent is relatively large, conformationally flexible, and lacks strong hydrogen bonding donors/acceptors directed towards the hinge region, which is often crucial for potent GSK3-beta inhibition. The phenoxy group adds lipophilicity and bulk, which might not be optimal for affinity or selectivity.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, the bulky and flexible 4-(phenoxy)pyrimidin-2-yl group can be replaced with a smaller heterocyclic group known to interact favorably with the kinase hinge region. A pyridine ring, specifically a pyridin-4-yl group, is a common bioisostere used in kinase inhibitors. The pyridine nitrogen can act as a hydrogen bond acceptor, potentially forming a key interaction with the hinge backbone NH, mimicking the adenine interaction of ATP.\",\n    \"Final_Target_Molecule\": \"Cn1c(-c2ccncc2)c(-c2ccc(F)cc2)c(=O)n1C\"\n  }\n]"
    },
    {
        "src_smiles": "COc1cc(OC)cc(-c2nnc(SCC(=O)c3ccccc3)o2)c1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central 1,3,4-oxadiazole ring. It is substituted at one position with a 3,5-dimethoxyphenyl group and at another position with a thioether linked acetophenone moiety (-SCC(=O)c3ccccc3). Key functional groups include the oxadiazole heterocycle, two methoxy groups, a thioether linkage, and a ketone.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves interactions within the ATP-binding site. The oxadiazole core can serve as a scaffold. The dimethoxyphenyl group might occupy a hydrophobic pocket. The thioacetophenone side chain offers potential interaction points, but its flexibility and chemical nature might not be optimal for strong binding or selectivity towards GSK3-beta.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The thioether linkage (-S-) is susceptible to metabolic oxidation (to sulfoxide or sulfone), potentially affecting pharmacokinetic properties and stability. Furthermore, this linker lacks hydrogen bonding capability directed towards the protein backbone, which is often crucial for kinase inhibition. The terminal phenyl ring lacks substituents that might enhance specific interactions within the active site.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition and metabolic stability, the thioether linker (-S-) can be replaced with an amine linker (-NH-). This introduces a hydrogen bond donor group, potentially forming favorable interactions with GSK3-beta active site residues (e.g., hinge region). This modification retains the overall pharmacophore structure while aiming for enhanced binding affinity and improved drug-like properties.\",\n    \"Final_Target_Molecule\": \"COc1cc(OC)cc(-c2nnc(NCc(=O)c3ccccc3)o2)c1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCCO3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrazolo[1,5-a]pyrimidine core substituted with an oxetanylmethoxy group at the pyrazole ring. This core is linked via a urea moiety (NC(=O)N) to a chiral 1-phenylethyl group.\",\n    \"Property_Analysis\": \"The pyrazolo[1,5-a]pyrimidine scaffold is a known hinge-binding motif in kinase inhibitors. The urea linker provides crucial hydrogen bond donors and acceptors for interaction within the ATP binding site. The oxetanyl group often enhances solubility and metabolic stability while potentially making specific interactions. The 1-phenylethyl group occupies a hydrophobic pocket.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 1-phenylethyl group, while occupying a hydrophobic pocket, may not provide optimal interactions for high GSK3-beta potency. Its size, shape, and lack of specific polar interactions might limit binding affinity compared to known optimal fragments for this region. The chirality also introduces potential issues with enantiomer-specific activity or separation.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, the 1-phenylethyl group is replaced. A 3-pyridyl group is introduced directly attached to the urea nitrogen. Pyridine rings are frequently found in potent GSK3-beta inhibitors, potentially forming favorable interactions (e.g., H-bonding via the nitrogen) within the active site pocket. This modification removes the chiral center and replaces the bulky hydrophobic group with a potentially more specific interacting moiety.\",\n    \"Final_Target_Molecule\": \"O=C(Nc1cc2[nH]nc(OCC3CCCO3)c2cn1)Nc1cccnc1\"\n  }\n]"
    },
    {
        "src_smiles": "COCc1nc(NC(=O)NC(C)c2ccccc2)cc2[nH]nc(OC)c12",
        "prop": "gsk",
        "json_results": "[{\n  \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrazolo[3,4-d]pyrimidine core. Key substituents include a methoxy group at C4, a methoxyethyl group at N1, and an N-((S)-1-phenylethyl)urea moiety attached to C6.\",\n  \"Property_Analysis\": \"The pyrazolo[3,4-d]pyrimidine core is a known scaffold for kinase inhibitors, potentially interacting with the hinge region of GSK3-beta. The urea group can form hydrogen bonds in the ATP binding site. The (S)-1-phenylethyl group likely occupies a hydrophobic pocket, and the N1/C4 substituents influence solubility and interactions within the binding site.\",\n  \"Limitation_in_Source_Molecule_for_Property\": \"The C4-methoxy group might not be optimal for potency compared to halogens or other groups often found in kinase inhibitors. The N1-methoxyethyl group might offer suboptimal hydrophobic interactions or introduce excessive flexibility. The phenyl group in the tail might lack specific interactions achievable with heterocyclic replacements.\",\n  \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition: 1. Replace the C4-methoxy group with a chlorine atom to improve hydrophobic interactions and electronic properties. 2. Replace the N1-methoxyethyl group with an isopropyl group for better hydrophobic packing. 3. Replace the terminal phenyl ring with a 3-pyridyl ring to introduce a potential hydrogen bond acceptor and modulate polarity.\",\n  \"Final_Target_Molecule\": \"CC(C)n1c(Cl)c2c(nc(NC(=O)NC(C)c3cccnc3)cn2)n1\"\n}]"
    },
    {
        "src_smiles": "CC(=O)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "prop": "gsk",
        "json_results": "[{\n  \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, CC(=O)Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1, features a pyrazolo[3,4-d]pyrimidine core. Key substituents include an acetamide group on the pyrazole ring, a 2,6-dichlorophenyl group attached to the pyrimidine ring at position 4, and an N-methyl group on the pyrimidine ring.\",\n  \"Property_Analysis\": \"The pyrazolo[3,4-d]pyrimidine scaffold is a known hinge-binding motif in many kinase inhibitors, mimicking the adenine moiety of ATP. The dichlorophenyl group likely occupies a hydrophobic pocket within the ATP binding site. The acetamide group potentially forms hydrogen bonds or interacts with the solvent-exposed region. GSK3-beta inhibitors often utilize such heterocyclic cores.\",\n  \"Limitation_in_Source_Molecule_for_Property\": \"The acetamide group (CC(=O)NH-) might not be optimal for interactions within the GSK3-beta active site. Its flexibility and hydrogen bonding capacity might be improved or altered for better potency or selectivity. The specific 2,6-dichloro substitution on the phenyl ring might also not provide the best fit or interaction profile compared to other substitution patterns or different aromatic groups.\",\n  \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, the acetamide group will be modified. Replacing it with a small, conformationally constrained group like a cyclopropylamino group can explore different interactions in that region, potentially enhancing binding affinity or improving pharmacokinetic properties by reducing metabolic lability compared to the acetyl group.\",\n  \"Final_Target_Molecule\": \"c1cc1Nc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1\"\n}]"
    },
    {
        "src_smiles": "O=C(Nc1ccc(Cl)cc1)Nc1ccc(C(F)(F)F)cc1Cl",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, N-(4-chlorophenyl)-N'-(3-chloro-4-(trifluoromethyl)phenyl)urea (SMILES: O=C(Nc1ccc(Cl)cc1)Nc1ccc(C(F)(F)F)cc1Cl), is a diaryl urea derivative. It features two phenyl rings linked by a urea moiety. One ring is substituted with chlorine at the para position. The other ring is substituted with a trifluoromethyl group at the para position and a chlorine atom at the meta position relative to the urea linkage.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition is the target property. Diaryl ureas are established scaffolds for kinase inhibitors, including GSK3-beta inhibitors. They typically bind to the ATP-binding site, forming key hydrogen bonds via the urea NH groups and making hydrophobic interactions with the surrounding pocket.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The specific substitution pattern, particularly the 3-chloro-4-(trifluoromethyl)phenyl group, might not be optimal for potent and selective GSK3-beta inhibition. The meta-chlorine atom could introduce steric hindrance or unfavorable electronic interactions within the GSK3-beta active site, potentially reducing binding affinity compared to simpler substitution patterns like 4-(trifluoromethyl)phenyl.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, remove the chlorine atom at the 3-position (meta) of the 4-(trifluoromethyl)phenyl ring. This simplification maintains the key 4-(trifluoromethyl)phenyl and 4-chlorophenyl motifs often found in potent kinase inhibitors while potentially removing steric or electronic clashes caused by the meta-chlorine. This modification aims to enhance binding affinity to the GSK3-beta active site.\",\n    \"Final_Target_Molecule\": \"O=C(Nc1ccc(Cl)cc1)Nc1ccc(C(F)(F)F)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "CCN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)CC1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule is a fluoroquinolone derivative. Key features include: a 4-quinolone core, a carboxylic acid group at position 3, a cyclopropyl group attached to the nitrogen at position 1, a fluorine atom at position 6, an N-ethylpiperazine ring at position 7, and a methoxy group at position 8.\",\n    \"Property_Analysis\": \"Fluoroquinolones are known kinase inhibitors. The carboxylic acid and the carbonyl oxygen at position 4 often interact with the hinge region of kinases. The N1-cyclopropyl group and the C7-piperazine substituent modulate potency and pharmacokinetic properties. The C6-fluorine generally enhances potency. The C8-methoxy group's impact on GSK3-beta inhibition can vary; sometimes, smaller or hydrogen substituents are preferred at this position.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The methoxy group at position 8 might introduce steric hindrance or unfavorable electronic interactions within the GSK3-beta active site compared to a hydrogen atom or other smaller substituents. SAR studies on similar quinolones often show that C8-H derivatives can exhibit improved activity against certain kinases.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, the methoxy group at position 8 will be removed and replaced with a hydrogen atom. This modification aims to reduce potential steric clashes and optimize interactions within the enzyme's active site, based on common SAR trends for quinolone-based kinase inhibitors.\",\n    \"Final_Target_Molecule\": \"CCN1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2)CC1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a chiral (1-phenylethyl)amino group linked via a urea bridge to an imidazo[1,2-b]pyridazine core. The imidazo[1,2-b]pyridazine core is substituted at the 6-position (based on standard numbering) with the urea linker and at the 3-position with a (3,3,3-trifluoropropyl)aminomethyl group.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves heterocyclic scaffolds capable of hydrogen bonding with the hinge region of the kinase ATP binding site. The urea linker can provide crucial hydrogen bond donor/acceptor interactions. The side chains (1-phenylethyl and trifluoroethylaminomethyl) occupy hydrophobic and specificity pockets within the active site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The trifluoroethyl group, while potentially enhancing metabolic stability or lipophilicity, might not be optimal for fitting into the specific sub-pocket targeted by the side chain at position 3 of the imidazo[1,2-b]pyridazine core. Its size, polarity, or conformational flexibility might limit binding affinity compared to other substituents.\",\n    \"Optimization_for_Source_Molecule\": \"Optimize the side chain at position 3 of the imidazo[1,2-b]pyridazine core. Replace the (3,3,3-trifluoropropyl)aminomethyl group with a different moiety known to interact favorably within kinase active sites, potentially offering better shape complementarity or specific interactions. A cyclopropylmethylamino group is chosen as a common, relatively small, and conformationally relevant substituent often explored in kinase inhibitor optimization.\",\n    \"Final_Target_Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(CNC3CC3)c2cn1)c1ccccc1\"\n  }\n]"
    },
    {
        "src_smiles": "COC(C)(C)COc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "[{\n  \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features an imidazo[1,2-a]pyridine core. Attached to the imidazole nitrogen (position 1 inferred from numbering convention, though exact attachment needs confirmation, assuming N1) is a tert-butoxyethoxy group (COC(C)(C)CO-). Position 6 of the imidazopyridine core bears an urea linkage (-NHC(=O)NH-) connected to a chiral (S)-1-phenylethylamine moiety.\",\n  \"Property_Analysis\": \"Imidazo[1,2-a]pyridine scaffolds are known privileged structures in kinase inhibition, potentially interacting with the ATP binding site hinge region. The urea group acts as a hydrogen bond donor/acceptor, crucial for binding kinases. The chiral amine and phenyl group likely occupy a hydrophobic pocket adjacent to the ATP site. The tert-butoxyethoxy group might interact with the solvent-exposed region or a specific sub-pocket.\",\n  \"Limitation_in_Source_Molecule_for_Property\": \"The unsubstituted phenyl ring in the (S)-1-phenylethylamine moiety might offer suboptimal hydrophobic interactions or lack specific interactions within the GSK3-beta binding pocket. Furthermore, the bulky tert-butoxyethoxy group could potentially lead to steric clashes or unfavorable ADME properties (like metabolic instability) without contributing significantly to affinity.\",\n  \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, introduce electron-withdrawing or halogen substituents onto the phenyl ring to modulate electronic properties and potentially form specific interactions (like halogen bonds) or improve metabolic stability. Replacing the phenyl group with a 4-fluorophenyl group is a common strategy to improve potency or pharmacokinetic properties by filling the pocket more effectively and potentially forming favorable interactions with the protein.\",\n  \"Final_Target_Molecule\": \"COC(C)(C)COc1n[nH]c2cc(NC(=O)NC(C)c3ccc(F)cc3)ncc12\"\n}]"
    },
    {
        "src_smiles": "O=C(Nc1ncc(CCNc2ncnc3ccsc23)s1)NC1CCCCC1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central thiazole ring. One nitrogen of the thiazole is substituted with an ethylamine linker connected to a thienopyrimidine core (specifically, thieno[2,3-d]pyrimidine). The carbon adjacent to the thiazole sulfur is substituted with a urea group, which is further substituted with a cyclohexyl ring.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often target the ATP binding site. Key interactions typically involve hydrogen bonding with the hinge region (e.g., Val135 backbone), hydrophobic interactions, and potentially cation-pi or pi-pi stacking. The thienopyrimidine core is a known hinge-binding motif in kinases. The urea group provides hydrogen bond donors/acceptors. The cyclohexyl group occupies a hydrophobic region.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The cyclohexyl group, while hydrophobic, lacks specific directional interactions (like pi-stacking) and its flexibility might lead to an entropic penalty upon binding. The overall lipophilicity might be high, potentially affecting solubility or pharmacokinetic properties. The specific substitution pattern and linker might not optimally position the thienopyrimidine core in the ATP site for maximum interaction.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve interactions and optimize properties, the flexible, purely aliphatic cyclohexyl ring can be replaced with a rigid aromatic ring, such as a phenyl group. This retains a hydrophobic character but introduces the possibility of pi-stacking interactions within the binding pocket, potentially increasing binding affinity. This modification maintains the core scaffold and key hydrogen bonding elements (urea, thienopyrimidine).\",\n    \"Final_Target_Molecule\": \"O=C(Nc1ncc(CCNc2ncnc3ccsc23)s1)Nc1ccccc1\"\n  }\n]"
    },
    {
        "src_smiles": "O=C(Nc1cc(-c2ccccc2)ccc1O)c1ccc(CN2CCOCC2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central amide linker connecting two main fragments: 1) A substituted biphenyl system containing a hydroxyl group (`-c1cc(-c2ccccc2)ccc1O`) attached to the amide nitrogen. 2) A para-substituted phenyl ring bearing a methylenemorpholine group (`-c1ccc(CN2CCOCC2)cc1`) attached to the amide carbonyl.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition typically involves interactions within the ATP-binding site, including hydrogen bonds with hinge residues (e.g., Val135) and catalytic residues (e.g., Lys85), as well as hydrophobic interactions. The source molecule possesses potential H-bond donors/acceptors (amide NH/C=O, hydroxyl -OH, morpholine oxygen/nitrogen) and hydrophobic groups (aromatic rings).\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The bulky and relatively flexible biphenyl-hydroxyl moiety might not optimally fit the specific shape and polarity requirements of the GSK3-beta active site, particularly the hinge region. It may lack specific directional interactions crucial for high potency and selectivity. The morpholine group, while aiding solubility, might not contribute significantly to binding affinity or could introduce steric hindrance.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, replace the biphenyl-hydroxyl group with a moiety known to interact effectively with the kinase hinge region. A common strategy involves incorporating smaller, nitrogen-containing heterocycles. Substituting the `c1cc(-c2ccccc2)ccc1O` group with a 4-pyridyl group (`c1ccncc1`) introduces a nitrogen atom positioned to potentially form a hydrogen bond with the hinge backbone amide NH of Val135, a key interaction for many GSK3-beta inhibitors, while retaining the core amide linker and the benzylmorpholine fragment.\",\n    \"Final_Target_Molecule\": \"O=C(Nc1ccncc1)c1ccc(CN2CCOCC2)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1ccc(C(O)(Cn2ccnc2)c2ccc(Br)cc2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central chiral carbon bearing a hydroxyl group, a methoxy-substituted phenyl ring, a bromo-substituted phenyl ring, and a methylene-linked 1,2,4-triazole ring. Key functional groups include a tertiary alcohol, an ether (methoxy), an aromatic bromide, and a triazole heterocycle.\",\n    \"Property_Analysis\": \"The molecule possesses structural elements often found in kinase inhibitors, including heterocyclic rings (triazole) and substituted aryl groups capable of various interactions (pi-stacking, hydrophobic, hydrogen bonding via the alcohol). These features suggest potential for interaction with the ATP-binding site of kinases like GSK3-beta. The triazole nitrogen atoms and the hydroxyl group can act as hydrogen bond acceptors/donors.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The bromine atom on the phenyl ring might not be optimal for binding affinity or selectivity towards GSK3-beta. Halogens can sometimes introduce metabolic liabilities or suboptimal steric/electronic interactions within the specific binding pocket. The overall lipophilicity contributed by the bromo and methoxy groups might also require optimization for improved pharmacokinetic properties or target engagement.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially enhance GSK3-beta inhibition, the bromine atom can be replaced with a different substituent. Replacing bromine with a cyano group (-C#N) is a common strategy in kinase inhibitor optimization. The cyano group is smaller, can act as a hydrogen bond acceptor, and alters the electronic properties of the phenyl ring, potentially leading to improved interactions with key residues in the GSK3-beta active site compared to the bromine atom.\",\n    \"Final_Target_Molecule\": \"COc1ccc(C(O)(Cn2ccnc2)c2ccc(C#N)cc2)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)CCN1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a core quinolone structure functionalized with a carboxylic acid group at position 3, an N-cyclopropyl group at position 1, and a piperazine ring attached at position 7 via a substituted phenyl ring. The phenyl ring contains fluorine and chlorine substituents. The piperazine ring is further substituted with a methyl group on the distal nitrogen atom.\",\n    \"Property_Analysis\": \"The quinolone core with the carboxylic acid is a common pharmacophore for kinase inhibition, potentially interacting with the ATP binding site of GSK3-beta. The carboxylic acid can form crucial hydrogen bonds. The N-cyclopropyl group and halogen substituents influence potency and pharmacokinetic properties. The piperazine moiety extends into a solvent-exposed region or adjacent subpocket, and its substituent (methyl group) significantly impacts binding affinity and selectivity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The methyl group on the piperazine ring might not be optimal for GSK3-beta inhibition. This position is often critical for potency and selectivity in kinase inhibitors, and a simple methyl group may offer limited interactions or suboptimal steric/electronic properties compared to larger or more functionalized groups. While the core structure is suitable, the specific substituent on the piperazine limits the potential for high-affinity binding to GSK3-beta.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition, the methyl group on the distal nitrogen of the piperazine ring will be replaced. This position allows exploration of interactions in the solvent-accessible region or nearby pockets. Replacing the methyl with a small aromatic or heteroaromatic ring, such as pyridine, can introduce beneficial pi-stacking interactions or hydrogen bonding capabilities, potentially improving affinity and selectivity for GSK3-beta. A 3-pyridyl group is chosen as it can act as a hydrogen bond acceptor and fits well sterically in similar kinase inhibitor scaffolds.\",\n    \"Final_Target_Molecule\": \"c1cnccc1C1CN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)CCN1\"\n  }\n]"
    },
    {
        "src_smiles": "CN1CCN(c2ncc3nc(CCc4ccccc4)c(=O)n(C)c3n2)CC1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, CN1CCN(c2ncc3nc(CCc4ccccc4)c(=O)n(C)c3n2)CC1, features a purine-like core (specifically, a 6-substituted hypoxanthine derivative). Key components include: 1) A hypoxanthine core methylated at N7. 2) A phenylethyl group attached at C8. 3) An N-methylpiperazine group attached at C6.\",\n    \"Property_Analysis\": \"GSK3-beta is a serine/threonine kinase. Inhibitors typically target the ATP-binding site, forming hydrogen bonds with the hinge region (e.g., Val135 backbone) and engaging in hydrophobic interactions. The source molecule has potential hydrogen bond acceptors (N1, N3, N9, C2=O, piperazine nitrogens) and hydrophobic groups (phenylethyl, piperazine ring, N-methyl group).\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The N-methylpiperazine group at C6 might not be optimal for GSK3-beta inhibition. While potentially conferring solubility or CNS penetration, it might introduce steric bulk or lack specific favorable interactions (like strong hydrogen bonds) with the hinge region or adjacent pockets compared to groups found in potent GSK3-beta inhibitors. Its flexibility could also be entropically unfavorable.\",\n    \"Optimization_for_Source_Molecule\": \"To improve potential interactions with the hinge region and potentially reduce steric bulk or unfavorable interactions associated with the N-methylpiperazine group, replace it with a smaller group capable of hydrogen bonding. Replacing the N-methylpiperazine with an amino (-NH2) group introduces potential hydrogen bond donor/acceptor capabilities directly at the C6 position, which is often critical for kinase hinge binding.\",\n    \"Final_Target_Molecule\": \"Nc1ncc2nc(CCc3ccccc3)c(=O)n(C)c2n1\"\n  }\n]"
    },
    {
        "src_smiles": "CCC(C)(C)Nc1c(C#N)cnc2cnc(NCc3cccnc3)cc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrrolo[2,3-b]pyridine core. Key substituents include a tert-pentylamino group at position 7, a cyano group at position 6, and a (pyridin-3-ylmethyl)amino group attached via a methylene linker at position 2.\",\n    \"Property_Analysis\": \"The pyrrolo[2,3-b]pyridine core likely serves as a hinge-binding motif common in kinase inhibitors. The pyridin-3-ylmethyl group can interact with the solvent-exposed region, potentially forming hydrogen bonds via the pyridine nitrogen. The bulky tert-pentylamino group occupies a hydrophobic pocket near the hinge region. The cyano group is an electron-withdrawing group and a potential hydrogen bond acceptor.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The cyano group, while a potential H-bond acceptor, might not be optimal for interaction within the specific GSK3-beta active site compared to other polar groups. The bulk and specific shape of the tert-pentyl group might not perfectly fit the hydrophobic pocket, potentially limiting potency. The flexibility of the methylene linker in the C2 substituent might lead to entropic penalties upon binding.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, replace the cyano group at C6 with a primary amide group (C(=O)NH2). Amides can offer stronger and more directional hydrogen bonding interactions compared to nitriles, potentially forming favorable contacts within the active site, a common optimization strategy for kinase inhibitors.\",\n    \"Final_Target_Molecule\": \"CCC(C)(C)Nc1c(C(=O)N)cnc2cnc(NCc3cccnc3)cc12\"\n  }\n]"
    },
    {
        "src_smiles": "CC(C(=O)Nc1ncc(SCc2ncc(C(C)(C)C)o2)s1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central aminothiazole scaffold. It is N-acylated with a phenylalaninyl group (CC(c1ccccc1)C(=O)N-). The thiazole ring is substituted at the 5-position with a methylsulfanylmethyl group (-SCc2...) linked to a 5-tert-butyl-oxazole ring.\",\n    \"Property_Analysis\": \"The molecule possesses several features relevant for kinase inhibition, including potential hydrogen bond donors/acceptors (amide NH, amide C=O, thiazole N, oxazole N) and hydrophobic groups (phenyl, tert-butyl). The aminothiazole core is common in kinase inhibitors. The thioether linker provides flexibility. GSK3-beta inhibitors often interact with the hinge region via hydrogen bonds and occupy hydrophobic pockets within the ATP binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The thioether linker (-S-) might be metabolically labile (oxidation to sulfoxide/sulfone) and does not offer directional hydrogen bonding. The bulky tert-butyl group on the oxazole might not be optimal for fitting into the relevant hydrophobic pocket of GSK3-beta or could introduce undesirable ADME properties. The overall binding affinity might need improvement.\",\n    \"Optimization_for_Source_Molecule\": \"To improve metabolic stability and potentially introduce favorable interactions, replace the thioether linker (-S-) with an amine linker (-NH-). This adds a hydrogen bond donor and removes the oxidation liability. To explore alternative hydrophobic interactions and potentially improve fit/properties, replace the sterically demanding tert-butyl group on the oxazole ring with a cyclopropyl group, a common bioisostere.\",\n    \"Final_Target_Molecule\": \"CC(C(=O)Nc1ncc(NCc2ncc(C3CC3)o2)s1)c1ccccc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(C)n1cnc2c(NCc3ccccc3)nc(I)nc21",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule has a purine core structure. An isopropyl group is attached at the N9 position. A benzylamine group (-NCc3ccccc3) is attached at the C6 position. An iodine atom (I) is attached at the C8 position.\",\n    \"Property_Analysis\": \"The target property is GSK3-beta inhibition. Purine derivatives are known kinase inhibitors, often binding to the ATP site. Key interactions typically involve hydrogen bonding with the hinge region via the purine nitrogens and the C6 substituent, and hydrophobic interactions involving the N9 and C8 substituents.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The iodine atom at the C8 position is large and primarily hydrophobic. While it can occupy hydrophobic pockets, it lacks strong hydrogen bonding capability which might be beneficial for potency. Large halogens like iodine can sometimes lead to lower selectivity or metabolic instability compared to smaller groups.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the iodine atom at C8 with a smaller halogen, chlorine (Cl). Chlorine is less sterically demanding than iodine, potentially allowing for a better fit in the GSK3-beta active site. It maintains halogen character which can participate in halogen bonding or hydrophobic interactions, potentially improving affinity and metabolic profile compared to iodine.\",\n    \"Final_Target_Molecule\": \"CC(C)n1cnc2c(NCc3ccccc3)nc(Cl)nc21\"\n  }\n]"
    },
    {
        "src_smiles": "COCCSc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features an imidazo[4,5-c]pyridine core. Position 1 is substituted with a methoxyethylthiomethyl group (COCCSC-). Position 6 is substituted with a urea linker connecting to a chiral alpha-methylbenzyl group (-NC(=O)N[CH](C)Ph). Key features include the heterocyclic core (potential hinge binder), the urea group (H-bond donor/acceptor), the chiral center, and the lipophilic phenyl ring. The N1 substituent contains a flexible chain with ether and thioether linkages.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves interactions with the ATP binding site. The imidazo[4,5-c]pyridine core, particularly the N-H and adjacent nitrogen, likely mimics adenine and interacts with the kinase hinge region via hydrogen bonds. The urea group can form additional hydrogen bonds within the active site. The alpha-methylbenzyl group is expected to occupy a hydrophobic pocket near the gatekeeper residue. The N1 substituent likely projects towards the solvent-exposed region or ribose pocket and influences solubility and potentially affinity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The primary limitation is the thioether linkage (-S-) in the N1 substituent (COCCSC-). Thioethers are often metabolically labile, susceptible to oxidation (to sulfoxide and sulfone), which can alter activity, solubility, and pharmacokinetic profile. The flexibility of the N1 side chain might also lead to an entropic penalty upon binding, potentially reducing affinity.\",\n    \"Optimization_for_Source_Molecule\": \"To improve metabolic stability and potentially optimize interactions, the thioether linkage in the N1 substituent will be replaced. An ether linkage (-O-) is a suitable bioisostere for a thioether, generally offering greater metabolic stability while maintaining similar steric and electronic properties. Therefore, the methoxyethylthiomethyl group (COCCSC-) will be replaced with a methoxyethoxymethyl group (COCCOC-). This modification aims to enhance the molecule's pharmacokinetic profile without disrupting the core binding interactions presumed necessary for GSK3-beta inhibition.\",\n    \"Final_Target_Molecule\": \"COCCOc1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCC3CCOCC3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrazolo[1,5-a]pyrimidine core, a common scaffold in kinase inhibitors. It is substituted with a urea linker (-NH-CO-NH-) attached to a chiral (R/S)-1-phenylethyl group (CC(c1ccccc1)N). The pyrimidine ring is further substituted with a tetrahydropyran (THP) group linked via an ether (-O-CH2-) to the pyrazole part of the core.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often interact with the ATP binding site. The pyrazolo[1,5-a]pyrimidine core likely orients within the binding site, potentially forming hydrogen bonds with the hinge region via the pyrazole NH or ring nitrogens. The urea linker provides additional hydrogen bond donors and acceptors. The chiral phenylethyl group and the THP-ether moiety likely occupy hydrophobic pockets adjacent to the main binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The THP-ether group (OCC3CCOCC3) is relatively bulky and flexible, which might not lead to optimal shape complementarity or specific interactions within its pocket, potentially limiting potency or selectivity. The unsubstituted phenyl ring might lack specific interactions that could enhance binding affinity. The overall combination might not achieve the highest possible affinity for the GSK3-beta active site compared to optimized analogues.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, we propose two modifications: 1) Replace the bulky and flexible THP-ether group (OCC3CCOCC3) with a smaller, less flexible methoxy group (OC) to probe the pocket size and polarity requirements. 2) Introduce a para-fluoro substituent on the phenyl ring (c1ccc(F)cc1) to enhance hydrophobic interactions or induce favorable electronic effects within its binding pocket, a common strategy in kinase inhibitor optimization.\",\n    \"Final_Target_Molecule\": \"COc1nc2[nH]cc(cc2cn1)NC(=O)NC(C)c1ccc(F)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(=O)c1ccc(-c2cccc(COC3COc4nc([N+](=O)[O-])cn4C3)c2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central biphenyl core linking an acetylphenyl group on one side and a meta-substituted ether linkage on the other. The ether connects to a complex heterocyclic system: a 2,3-dihydrofuran ring fused to a pyridine ring which is substituted with a nitro group (specifically, a derivative of 2,3-dihydrofuro[2,3-b]pyridine or similar isomer). Key functional groups include the ketone (acetyl), biphenyl, ether, dihydrofuran, pyridine, and nitro group.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often target the ATP-binding site. The heterocyclic core (fused dihydrofuro-pyridine) likely occupies the adenine-binding region, potentially forming hydrogen bonds with hinge residues. The biphenyl group acts as a scaffold, positioning the terminal groups. The nitro group is strongly electron-withdrawing, influencing the electronics of the heterocycle. The acetyl group adds polarity and potential interaction points.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The primary limitation is the presence of the nitro group ([N+](=O)[O-]), which is often associated with metabolic instability and potential toxicity (e.g., mutagenicity), making it undesirable for drug development. Furthermore, the acetyl group's contribution to binding might be suboptimal, and the overall potency/selectivity/ADME profile may require improvement. The specific interactions mediated by the nitro and acetyl groups might not be optimal for high-affinity GSK3-beta binding.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition potential and drug-likeness, prioritize replacing the problematic nitro group. A common bioisosteric replacement is the cyano group (-C#N), which maintains electron-withdrawing character but avoids nitro-associated toxicity. Additionally, modify the acetyl group to potentially enhance interactions or improve properties. Replacing the acetyl group (CC(=O)-) with a carboxamide group (NC(=O)-) could introduce additional hydrogen bonding potential, often favorable for kinase inhibitors.\",\n    \"Final_Target_Molecule\": \"NC(=O)c1ccc(-c2cccc(COC3COc4nc(C#N)cn4C3)c2)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(CNCC(F)(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The molecule contains an imidazo[1,2-a]pyridine heterocyclic core. This core is substituted at one position with a (2,2,2-trifluoroethyl)aminomethyl group (-CNCC(F)(F)F). Another position is linked via a urea bridge (-NHC(=O)NH-) to a chiral secondary amine derived from 1-phenylethylamine (-CH(CH3)c1ccccc1).\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often target the ATP-binding site. The urea moiety provides crucial hydrogen bond donor/acceptor capabilities, likely interacting with the kinase hinge region (e.g., Asp133, Val135). The imidazopyridine core serves as a scaffold, positioning substituents into specific pockets. The trifluoroethyl group contributes lipophilicity and potential interactions via fluorine or the amine nitrogen. The chiral phenylethyl group occupies another pocket, influencing binding affinity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The trifluoroethyl group, while potentially binding, might not be optimal for interaction within the target pocket and could introduce metabolic liabilities or excessive lipophilicity. The phenyl group attached to the chiral center significantly increases lipophilicity (potentially reducing solubility or increasing off-target effects) and might not fit optimally within its corresponding subpocket for maximal GSK3-beta inhibition.\",\n    \"Optimization_for_Source_Molecule\": \"To enhance GSK3-beta inhibition and improve drug-like properties: 1. Replace the (2,2,2-trifluoroethyl)aminomethyl group with a morpholinomethyl group (-CN1CCOCC1). Morpholine often improves solubility and metabolic stability while providing hydrogen bond accepting capabilities. 2. Replace the phenyl group on the chiral amine with a smaller alkyl group, such as methyl, creating an isopropylamino substituent (-CH(CH3)CH3). This reduces lipophilicity and explores alternative steric interactions within the binding site.\",\n    \"Final_Target_Molecule\": \"CC(C)NC(=O)Nc1cc2[nH]nc(CN3CCOCC3)c2cn1\"\n  }\n]"
    },
    {
        "src_smiles": "Cc1ccccc1-c1ccc(CC2NC(=O)c3cc(Cl)ccc3N(C)C2=O)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a biphenyl system where one phenyl ring is substituted with a methyl group. This biphenyl moiety is connected via a methylene (-CH2-) linker to a complex heterocyclic core. This core appears to be a derivative related to maleimide or a similar dione structure, containing an N-methyl group and substituted with a chlorophenyl ring (`NC(=O)c3cc(Cl)ccc3N(C)C2=O`). Key functional groups include the biphenyl unit, the methylene linker, the amide/imide carbonyls, the N-methyl group, and the chlorophenyl substituent.\",\n    \"Property_Analysis\": \"The molecule contains structural motifs often found in kinase inhibitors, particularly GSK3-beta inhibitors. The maleimide-like core is a known pharmacophore for GSK3-beta inhibition, potentially interacting with the ATP binding site via hydrogen bonding and hydrophobic interactions. The chlorophenyl and biphenyl groups likely occupy hydrophobic pockets within the active site. The N-methyl group may influence conformation or interact with the protein.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The existing methyl group on the terminal phenyl ring might not be optimal for hydrophobic interactions or could introduce metabolic liabilities. The flexibility of the methylene linker might lead to an entropic penalty upon binding. The overall lipophilicity contributed by the biphenyl and chlorophenyl groups might affect solubility or pharmacokinetic properties. The specific substitution pattern might not be fully optimized for maximizing interactions within the GSK3-beta active site.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, the terminal phenyl ring of the biphenyl system will be modified. The methyl group will be replaced with a fluorine atom. Fluorine is similar in size to hydrogen but offers different electronic properties (electron-withdrawing) and can form favorable interactions (like halogen bonds or specific hydrophobic interactions). It can also improve metabolic stability and potentially enhance binding affinity without significantly increasing size.\",\n    \"Final_Target_Molecule\": \"Fc1ccccc1-c1ccc(CC2NC(=O)c3cc(Cl)ccc3N(C)C2=O)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "COCC(O)CNC(=O)c1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, COCC(O)CNC(=O)c1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12, features an imidazo[4,5-b]pyridine core. Attached to the pyridine part of the core (likely position 6) is a urea linkage (NC(=O)N) connected to a chiral alpha-methylbenzyl group. Attached to the imidazole part of the core (likely position 3) via an amide bond (C(=O)N) is a flexible, polar 1-methoxy-3-amino-propan-2-ol side chain.\",\n    \"Property_Analysis\": \"The imidazopyridine core is a known scaffold for kinase inhibitors, potentially interacting with the hinge region of GSK3-beta. The urea group and the chiral alpha-methylbenzyl moiety likely engage in hydrogen bonding and hydrophobic interactions within the ATP-binding site, common features for kinase inhibition. The overall structure suggests potential ATP-competitive inhibition of GSK3-beta.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 1-methoxy-3-(amide)-propan-2-ol side chain (COCC(O)CNC(=O)-) attached to the imidazopyridine core is highly flexible and polar. This may lead to suboptimal binding affinity due to entropic penalties or poor complementarity with the binding pocket. Additionally, its polarity and potential metabolic liabilities (ether, secondary alcohol) could negatively impact cell permeability, bioavailability, and overall drug-like properties, hindering effective GSK3-beta inhibition in a biological context.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition and drug-like properties, the flexible and polar COCC(O)CN group attached to the amide linker will be replaced. Substitution with a smaller, more rigid, and potentially less polar group like cyclopropyl can enhance binding affinity by reducing conformational flexibility and improving hydrophobic interactions within the pocket. Cyclopropyl groups are also often associated with improved metabolic stability compared to linear alkyl chains with heteroatoms.\",\n    \"Final_Target_Molecule\": \"C1CC1C(=O)c1n[nH]c2cc(NC(=O)NC(C)c3ccccc3)ncc12\"\n  }\n]"
    },
    {
        "src_smiles": "CNc1ncnc(-c2cccnc2Oc2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2C)n1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, CNc1ncnc(-c2cccnc2Oc2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2C)n1, features a 2-(methylamino)pyrimidine core, which can act as a hinge-binder in kinases. This core is linked via a 4-(pyridin-3-yloxy) substituent to a 2-methyl-5-(3-(trifluoromethyl)phenylcarbamoyl)phenyl group. Key components include the pyrimidine nitrogen atoms (potential H-bond acceptors), the methylamino group (potential H-bond donor/acceptor), the pyridine nitrogen (potential H-bond acceptor), the ether linkage, the amide group (H-bond donor/acceptor), and the trifluoromethyl group (lipophilic interactions).\",\n    \"Property_Analysis\": \"The molecule contains structural motifs common in kinase inhibitors targeting the ATP binding site. The 2-aminopyrimidine derivative is expected to interact with the kinase hinge region. The extended substituted phenyl ring system connected via the pyridine-ether linker likely occupies the hydrophobic pocket and interacts with residues near the gatekeeper. GSK3-beta inhibition often relies on strong hinge binding and appropriate occupancy of adjacent hydrophobic pockets.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The N-methyl group on the 2-amino position of the pyrimidine might limit potency. While it provides one hydrogen bond donor, a primary amine (NH2) can offer two hydrogen bond donors, potentially forming a more stable interaction with the kinase hinge backbone (e.g., Val135 in GSK3-beta). This single methyl group might also introduce unfavorable steric interactions or suboptimal positioning within the hinge region compared to NH2.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially enhance interaction with the GSK3-beta hinge region, the N-methyl group on the pyrimidine ring will be replaced with a hydrogen atom. This converts the secondary amine (-NHMe) to a primary amine (-NH2). This modification aims to enable dual hydrogen bond donation to the hinge backbone residues, a common strategy for improving the binding affinity of kinase inhibitors.\",\n    \"Final_Target_Molecule\": \"Nc1ncnc(-c2cccnc2Oc2cc(C(=O)Nc3cccc(C(F)(F)F)c3)ccc2C)n1\"\n  }\n]"
    },
    {
        "src_smiles": "CCOC(=O)C1(C(=O)NC(Cc2ccc(-c3ccccc3OC)cc2)C(=O)O)CCCO1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a spirocyclic core containing an oxetane fused with a lactone-like ring bearing an ethyl ester. This core is linked via an amide bond to an N-acylated amino acid derivative. The amino acid component possesses a free carboxylic acid and a side chain consisting of a benzyl group substituted with a para-phenoxy group where the terminal phenyl ring has a meta-methoxy substituent.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves molecules that can interact with the ATP binding site. Key interactions typically include hydrogen bonds with the hinge region residues (e.g., Val135) and interactions within the hydrophobic pocket and phosphate binding region. The source molecule possesses potential H-bond donors/acceptors (amide, carboxylic acid, ester, ether oxygens) and a large hydrophobic biphenyl ether side chain.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The spirocyclic oxetane-lactone core is not a common scaffold for potent GSK3-beta inhibitors and may not provide optimal geometry or interactions within the ATP binding site, particularly with the hinge region. The overall polarity and potential flexibility might hinder optimal binding affinity or cell permeability. The free carboxylic acid could lead to poor pharmacokinetic properties.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the complex spirocyclic core with a scaffold known to interact effectively with the GSK3-beta active site, such as a thiazolidinedione (TZD) ring, which can form relevant hydrogen bonds. Retain the hydrophobic biphenyl ether side chain, as it likely occupies a hydrophobic pocket, but attach it directly or via a simple linker to the TZD nitrogen atom to position it appropriately. The free carboxylic acid and ester group will be removed as part of the core replacement.\",\n    \"Final_Target_Molecule\": \"COc1ccccc1-c2ccc(CN3C(=O)SC(=O)C3)cc2\"\n  }\n]"
    },
    {
        "src_smiles": "CC(C)CC(NC(c1ccc(-c2ccc(C#N)cc2)cc1)C(F)(F)F)C(=O)NCC#N",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central chiral amine core derived from leucine. It is N-acylated with a group containing a biphenyl system substituted with a nitrile and a trifluoromethyl group at the alpha position. The C-terminus is an amide formed with cyanomethylamine. Key groups include: Isopropyl side chain, secondary amide, chiral center with CF3, biphenyl nitrile moiety, secondary amide, cyanomethyl group.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often feature heterocyclic moieties capable of specific hydrogen bonding interactions within the ATP binding site, particularly with the hinge region. The biphenyl nitrile provides a hydrophobic scaffold and potential polar interactions via the nitrile. The CF3 group increases lipophilicity and can influence binding conformation. The amides provide hydrogen bond donor/acceptor capabilities. The cyanomethylamide terminus is relatively small and polar.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The cyanomethylamide group (C(=O)NCC#N) might not be optimal for exploiting key interactions in the GSK3-beta active site. Specifically, it may lack the appropriate size, shape, or hydrogen bonding pattern commonly seen in potent inhibitors which often utilize heterocycles like thiazoles or pyridines to interact with hinge residues (e.g., Val135). The terminal nitrile could also be metabolically liable.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the cyanomethylamide moiety (NCC#N) with a group known to enhance GSK3-beta inhibition, such as a 2-thiazolyl group. This introduces a heterocycle capable of forming favorable hydrogen bonds and van der Waals interactions within the active site, mimicking interactions seen in known potent GSK3-beta inhibitors. The amide linkage is retained, connecting to the 2-amino position of the thiazole.\",\n    \"Final_Target_Molecule\": \"CC(C)CC(NC(c1ccc(-c2ccc(C#N)cc2)cc1)C(F)(F)F)C(=O)Nc1nccs1\"\n  }\n]"
    },
    {
        "src_smiles": "Cc1c(F)ccc(C(=O)Nc2cc(C(=O)O)ccc2N2CCN(C)CC2)c1Cl",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a 3-chloro-4-fluoro-5-methylphenyl group connected via an amide linker (-C(=O)NH-) to a central phenyl ring. This central ring is substituted with a carboxylic acid (-COOH) group and a N-methylpiperazine moiety.\",\n    \"Property_Analysis\": \"The molecule possesses key pharmacophoric elements often found in kinase inhibitors: hydrogen bond donors/acceptors (amide, COOH, piperazine nitrogens), an acidic group (COOH) likely interacting with basic residues (e.g., Lys85 in GSK3-beta), and hydrophobic groups (substituted phenyl, methyl). The N-methylpiperazine provides basicity and potential solubility enhancement.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 3-chloro-4-fluoro-5-methylphenyl group might not be optimal for fitting into the hydrophobic pocket or interacting with the hinge region of the GSK3-beta active site. The specific substitution pattern might lead to suboptimal binding affinity or introduce metabolic liabilities. The overall lipophilicity might need adjustment.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the 3-chloro-4-fluoro-5-methylphenyl moiety with a different aromatic or heteroaromatic system known to enhance binding to kinase active sites, particularly GSK3-beta. An indole scaffold is chosen, attached via its 3-position to the amide carbonyl. Indole NH can potentially form a hydrogen bond with the hinge region of the kinase, a common interaction motif for potent inhibitors. This modification aims to improve shape complementarity and add a key hydrogen bond interaction.\",\n    \"Final_Target_Molecule\": \"O=C(Nc1cc(C(=O)O)ccc1N1CCN(C)CC1)c2c[nH]c3ccccc23\"\n  }\n]"
    },
    {
        "src_smiles": "CN1CCN(CCCNc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)CC1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrido[2,3-d]pyrimidin-7(8H)-one core. Attached to the pyrimidine ring nitrogen (N8) is a methyl group. Position 6 of the pyridine ring bears a 2,6-dichlorophenyl substituent. Position 2 of the pyrimidine ring is connected to an N-methylpiperazine moiety via a propylamino linker (-NH-CH2-CH2-CH2-).\",\n    \"Property_Analysis\": \"The pyrido[2,3-d]pyrimidinone core acts as a hinge-binder, mimicking the adenine part of ATP, likely forming hydrogen bonds with the GSK3-beta hinge region (e.g., Val135 N-H and C=O). The 2,6-dichlorophenyl group occupies a hydrophobic pocket (gatekeeper residue Met134). The N-methylpiperazine group extends towards the solvent-exposed region, potentially interacting with charged or polar residues and influencing pharmacokinetic properties.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"While the core structure is suitable for kinase inhibition, the specific substituents might not be fully optimized for GSK3-beta affinity or selectivity. The 2,6-dichlorophenyl group, while providing hydrophobic interactions, might introduce metabolic liabilities or suboptimal interactions within the pocket compared to other potential substituents. The flexibility of the propyl linker and the nature of the piperazine group might not lead to the most favorable interactions in the solvent channel.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially enhance GSK3-beta inhibition, focus on modifying the substituent at position 6. Replacing the 2,6-dichlorophenyl group with a different aromatic or heteroaromatic system could improve binding affinity and selectivity. For instance, replacing one or both chlorine atoms with fluorine or trifluoromethyl groups can modulate electronic properties and potentially introduce favorable halogen bonding or hydrophobic interactions while possibly improving metabolic stability. Let's replace one chlorine with fluorine to create a 2-chloro-6-fluorophenyl group, aiming to fine-tune interactions in the hydrophobic pocket.\",\n    \"Final_Target_Molecule\": \"CN1CCN(CCCNc2ncc3cc(-c4c(F)cccc4Cl)c(=O)n(C)c3n2)CC1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1cccc(Cl)c1-c1ccc(COC2COc3nc([N+](=O)[O-])cn3C2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a biphenyl core substituted with methoxy and chloro groups on one phenyl ring. The other phenyl ring is connected via a methylene ether linker (-CH2-O-) to a dihydrofuropyrimidine heterocyclic system. This heterocycle is further substituted with a nitro group.\",\n    \"Property_Analysis\": \"The dihydrofuropyrimidine core is a potential hinge-binding motif for kinases like GSK3-beta, capable of forming hydrogen bonds. The nitro group acts as a strong electron-withdrawing group and potential hydrogen bond acceptor. The substituted biphenyl moiety likely occupies hydrophobic regions of the ATP binding site.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The primary limitation is the presence of the nitro group (-NO2), which is often associated with metabolic instability, potential toxicity (e.g., mutagenicity via reduction to reactive intermediates), and poor pharmacokinetic properties. This functional group is generally undesirable in drug candidates.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the metabolically labile and potentially toxic nitro group with a more stable bioisostere that retains or improves binding interactions. A cyano group (-C#N) is a suitable replacement, acting as a hydrogen bond acceptor and electron-withdrawing group but without the associated toxicity of the nitro group.\",\n    \"Final_Target_Molecule\": \"COc1cccc(Cl)c1-c1ccc(COC2COc3nc(C#N)cn3C2)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)N3CC(=O)N(C)C3)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features an imidazo[1,2-b]pyridazine core substituted at the C3 position with an N-methylpiperazinone amide (C(=O)N3CC(=O)N(C)C3) and at the C6 position via a urea linker (-NH-C(=O)-NH-) to a chiral 1-phenylethyl group (CC(C1=CC=CC=C1)-). The imidazo[1,2-b]pyridazine is a known kinase hinge-binding scaffold. The urea linker provides hydrogen bond donor/acceptor capabilities. The N-methylpiperazinone amide and the phenylethyl group likely occupy specific pockets within the target protein.\",\n    \"Property_Analysis\": \"The molecule is designed as a potential GSK3-beta inhibitor. The imidazo[1,2-b]pyridazine core likely interacts with the ATP binding site's hinge region. The urea linker and the C3 substituent contribute to binding affinity through hydrogen bonding and hydrophobic interactions within the active site. The chiral phenylethyl group probes a hydrophobic pocket.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The N-methylpiperazinone amide group at C3 might not be optimal for potency or pharmacokinetic properties (e.g., solubility, metabolic stability). Its size and polarity might limit interactions or lead to suboptimal ADME characteristics. The urea linker can sometimes be associated with metabolic instability or poor permeability.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition and properties, the C3 N-methylpiperazinone amide substituent can be replaced. A common strategy for optimizing GSK3-beta inhibitors involves introducing groups that can form favorable interactions, such as hydrogen bonds, with residues near the entrance of the ATP pocket. Replacing the complex amide with a smaller, rigid, polar heterocycle like pyridine is a viable approach. A 4-pyridyl group at the C3 position is known to be beneficial for GSK3-beta inhibition in similar scaffolds, potentially forming a hydrogen bond with the catalytic lysine or interacting favorably within the pocket.\",\n    \"Final_Target_Molecule\": \"CC(Nc1ccccc1)NC(=O)Nc1cc2c(cn1)nc(c3ccncc3)[nH]2\"\n  }\n]"
    },
    {
        "src_smiles": "COc1ccc(NC(=O)Cc2c(C)n(C(=O)c3ccc(Cl)cc3)c3ccc(OC)cc23)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features an indole core substituted at C2 with a methyl group and fused to a benzene ring bearing a methoxy group. The indole nitrogen is acylated with a 4-chlorobenzoyl moiety. An acetamide linker connects the indole C3 position to a 4-methoxyaniline ring.\",\n    \"Property_Analysis\": \"The molecule contains structural elements common in kinase inhibitors, such as the indole scaffold and amide linker, which can participate in hydrogen bonding within the ATP binding site. The N-acyl group and substituents modulate solubility, lipophilicity, and interactions within the kinase pocket. GSK3-beta inhibitors often utilize heterocyclic cores and specific hydrogen bonding patterns.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The N-(4-chlorobenzoyl) group might not be optimal for binding affinity or selectivity towards GSK3-beta compared to other heterocyclic systems known to interact strongly with the kinase hinge region. The overall lipophilicity might be high, potentially affecting pharmacokinetic properties. The specific substitution pattern might lack key interactions exploited by potent GSK3-beta inhibitors.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the N-(4-chlorobenzoyl) group with a pyrimidin-4-yl group. Pyrimidines are frequently found in potent GSK3-beta inhibitors, often forming crucial hydrogen bonds with the hinge region via their nitrogen atoms. This modification aims to improve interactions within the ATP binding site, potentially increasing potency and selectivity.\",\n    \"Final_Target_Molecule\": \"COc1ccc(NC(=O)Cc2c(C)n(c3cncnc3)c4ccc(OC)cc24)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1ccccc1N(C)c1cc[nH]c(=O)c1C(=O)Nc1ccc(N2CCN(C)CC2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a maleimide core substituted at C3 and C4. The C3 position bears an N-methyl-N-(methoxyphenyl)amino group (COc1ccccc1N(C)-). The C4 position is linked via an amide bond (-C(=O)NH-) to a phenyl ring, which is further substituted with an N-methylpiperazine group (-N1CCN(C)CC1). Key features include the maleimide ring (potential hinge binder), the amide linker, and the terminal basic N-methylpiperazine.\",\n    \"Property_Analysis\": \"The maleimide core is a known scaffold for kinase inhibitors, including GSK3-beta, often interacting with the hinge region via hydrogen bonds from the maleimide NH and carbonyls. The substituents at C3 and C4 determine interactions within adjacent pockets and solvent-exposed regions, influencing affinity and selectivity. The N-methylpiperazine tail often enhances solubility and provides polar interactions.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The C3 substituent (N-methyl-N-(methoxyphenyl)amino) is relatively bulky and flexible. This group might not fit optimally into the corresponding GSK3-beta binding pocket, potentially causing steric clashes or unfavorable interactions compared to smaller or more rigid substituents often found in potent inhibitors. Its specific electronic and steric profile might limit binding affinity or selectivity for GSK3-beta.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition, the C3 substituent (N-methyl-N-(methoxyphenyl)amino) can be replaced with a group known to form favorable interactions in this subpocket of GSK3-beta. Replacing it with a smaller, less flexible aryl group like 4-fluorophenyl can maintain aromatic interactions while potentially improving fit and introducing favorable halogen interactions, a common strategy in kinase inhibitor optimization. This modification targets the C3 pocket interaction without altering the potential hinge binding or the C4 tail interactions initially.\",\n    \"Final_Target_Molecule\": \"O=c1[nH]cc(c1C(=O)Nc1ccc(N2CCN(C)CC2)cc1)c1ccc(F)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "O=C(NC(Cc1ccc(O)cc1)C(=O)NCC1CC(Br)=NO1)OCc1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule is a peptide derivative containing a benzyloxycarbonyl (Cbz) protected N-terminus, a tyrosine residue (phenol group), a glycine linker, and a C-terminal 3-bromo-4,5-dihydroisoxazole group attached via the glycine nitrogen.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves interactions within the ATP-binding site, requiring hydrogen bond donors/acceptors and appropriate hydrophobic interactions. The tyrosine phenol, amide bonds, and potentially the isoxazoline nitrogen/oxygen could act as H-bond partners. The benzyl and phenyl rings provide hydrophobic contacts. The bromo-isoxazoline moiety is a less common fragment in known GSK3-beta inhibitors.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 3-bromo-4,5-dihydroisoxazole group might not be optimal for binding affinity or selectivity towards GSK3-beta. Its size, shape, and electronic properties (especially the bromine atom) may not fit well within the target binding pocket or establish key interactions compared to established GSK3-beta inhibitor scaffolds. The Cbz group, while providing structure, might also limit interactions or pose metabolic stability issues.\",\n    \"Optimization_for_Source_Molecule\": \"Replace the C-terminal 3-bromo-4,5-dihydroisoxazole moiety (connected via the glycine nitrogen) with a group known to provide beneficial interactions in kinase inhibitor design. A simple benzyl group attached to the glycine nitrogen could enhance hydrophobic interactions within the binding site, potentially improving affinity. This replaces `C1CC(Br)=NO1` with `c2ccccc2` on the glycine nitrogen.\",\n    \"Final_Target_Molecule\": \"O=C(NC(Cc1ccc(O)cc1)C(=O)NCc2ccccc2)OCc3ccccc3\"\n  }\n]"
    },
    {
        "src_smiles": "Cc1cc(C(N)=O)ccc1-n1c(CCC(=O)O)ccc1-c1ccc(-c2cnn(C)c2)cc1",
        "prop": "gsk",
        "json_results": "[{\n  \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central pyrrole ring. Attached to the pyrrole nitrogen (N1) is a 4-(aminocarbonyl)-3-methylphenyl group. Attached to a pyrrole carbon (likely C2 or C5) is a 3-carboxypropyl side chain (-CCC(=O)O). Attached to another pyrrole carbon (likely C4 or C3) is a phenyl ring, which is para-substituted with a 1-methyl-1H-pyrazol-4-yl group.\",\n  \"Property_Analysis\": \"GSK3-beta inhibition often involves interactions within the ATP binding site. Key pharmacophoric features in the source molecule include: potential hydrogen bond donors/acceptors (amide NH2, C=O; carboxylic acid OH, C=O; pyrrole N (if protonated), pyrazole Ns) and hydrophobic groups (methyl, phenyl rings). The pyrrole and pyrazole heterocycles are common motifs in kinase inhibitors.\",\n  \"Limitation_in_Source_Molecule_for_Property\": \"The carboxylic acid group (-CCC(=O)O) introduces a negative charge at physiological pH, which can hinder cell permeability and potentially lead to rapid clearance or metabolic liabilities (e.g., glucuronidation). Its length and flexibility might also not be optimal for fitting the binding pocket. The specific spatial arrangement of the H-bonding groups and hydrophobic elements might not be perfectly complementary to the GSK3-beta active site.\",\n  \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition and pharmacokinetic properties, the carboxylic acid group will be replaced with a non-acidic bioisostere, specifically an acetamide group attached via a methylene linker (-CH2C(O)=N), to maintain hydrogen bonding potential while improving permeability and metabolic stability. Additionally, a fluorine atom will be introduced onto the phenyl ring connecting the pyrrole and pyrazole (ortho to the pyrazole substituent) to potentially enhance binding affinity through favourable interactions or by modulating electronics and conformation.\",\n  \"Final_Target_Molecule\": \"Cc1cc(C(N)=O)ccc1-n1c(CC(=O)N)cc(-c2ccc(-c3cnn(C)c3)c(F)c2)c1\"\n}]"
    },
    {
        "src_smiles": "CN1C(=O)C(Cc2ccc(-c3ccccc3[N+](=O)[O-])cc2)NC(=O)c2cc(Cl)ccc21",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule, interpreted as 1-Methyl-3-[4-(3-nitrophenyl)benzyl]-6-chloroquinazoline-2,4(1H,3H)-dione (based on likely intent of the provided SMILES CN1C(=O)C(Cc2ccc(-c3ccccc3[N+](=O)[O-])cc2)NC(=O)c2cc(Cl)ccc21), features a quinazoline-2,4-dione core. Key substitutions include a methyl group at N1, a chloro group at C6, and a 4-(3-nitrophenyl)benzyl group at the N3 position.\",\n    \"Property_Analysis\": \"The quinazoline-2,4-dione core can potentially interact with the ATP binding site of GSK3-beta, mimicking adenine. The carbonyl oxygens can act as hydrogen bond acceptors. The N3-benzyl substituent extends into a hydrophobic pocket, and its specific interactions are influenced by the terminal 3-nitrophenyl group. The C6-chloro group likely contributes to binding affinity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The primary limitation is the presence of the nitro (-NO2) group on the terminal phenyl ring. Nitro groups are often associated with metabolic instability, potential toxicity (mutagenicity concerns after reduction), and poor pharmacokinetic properties, hindering its development as a drug candidate despite potential binding affinity.\",\n    \"Optimization_for_Source_Molecule\": \"Optimization focuses on replacing the metabolically labile and potentially toxic nitro group with a more favorable substituent while aiming to maintain or improve binding interactions. A suitable replacement is the sulfonamide group (-SO2NH2) at the same meta-position. Sulfonamides are common in kinase inhibitors, can act as hydrogen bond donors/acceptors, maintain electron-withdrawing character, and generally exhibit better safety and metabolic profiles compared to nitro groups.\",\n    \"Final_Target_Molecule\": \"CN1C(=O)N(Cc2ccc(-c3ccccc3S(=O)(=O)N)cc2)C(=O)c2cc(Cl)ccc21\"\n  }\n]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(C(=O)NCC(O)C(F)F)c2cn1)c1ccccc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrazolo[1,5-a]pyrimidine core scaffold. Key substituents include: 1) An N-(1-phenylethyl)urea group attached at the C6 position of the pyrimidine ring. 2) A complex amide group, -C(=O)NCC(OH)C(F)F, attached at the C3 position of the pyrazole ring.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often relies on interactions with the ATP binding site. The pyrazolo[1,5-a]pyrimidine scaffold can act as a hinge binder via its nitrogen atoms. The urea group provides hydrogen bond donors and acceptors. The amide side chain and the phenylethyl group occupy adjacent pockets, contributing through polar (OH, F, C=O, NH) and hydrophobic (phenyl, ethyl) interactions.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The N-(1-phenylethyl)urea moiety might introduce excessive flexibility or suboptimal steric/hydrophobic interactions within its binding pocket. The complex amide side chain (-C(=O)NCC(OH)C(F)F) might not be optimal in terms of vector, polarity, or hydrogen bonding potential for strong interaction with the specific residues in the GSK3-beta active site targeted by this region. The overall combination might lead to moderate potency or lack selectivity.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, we can simplify or replace the substituents. Replace the bulky and flexible N-(1-phenylethyl)urea group at C6 with a simpler hydrogen bond donor/acceptor group known to interact favorably in kinase inhibitors, such as a simple amino group (-NH2). Replace the complex amide side chain at C3 with a group known to effectively target the corresponding pocket in GSK3-beta, such as a 4-pyridyl group, which offers hydrogen bond accepting capability and favorable aromatic interactions.\",\n    \"Final_Target_Molecule\": \"Nc1cc2[nH]nc(c3ccncc3)c2cn1\"\n  }\n]"
    },
    {
        "src_smiles": "CCCCCCNc1ncc2cc(-c3c(Cl)cccc3Cl)c(=O)n(C)c2n1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a fused purine-like scaffold (imidazo[4,5-d]pyrimidine-7-one). Key substituents include an n-hexylamino group at position 6, a 2,6-dichlorophenyl group at position 8, and an N-methyl group at position 9.\",\n    \"Property_Analysis\": \"This scaffold is common among kinase inhibitors. The 2,6-dichlorophenyl group likely occupies a hydrophobic pocket near the ATP binding site. The amino group at position 6 is positioned to potentially interact with the kinase hinge region via hydrogen bonding. The N-methyl group fills a specific pocket or orients other substituents. The n-hexyl chain contributes significantly to lipophilicity and might interact with a hydrophobic channel or solvent.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The long, flexible n-hexyl chain on the C6-amino group may lead to suboptimal hinge interactions due to conformational flexibility. Its high lipophilicity can negatively impact physicochemical properties (e.g., solubility, permeability) and potentially lead to off-target binding or poor pharmacokinetic profiles. It might not be the optimal length or nature for the specific GSK3-beta binding site.\",\n    \"Optimization_for_Source_Molecule\": \"To improve GSK3-beta inhibition and potentially enhance drug-like properties, the flexible and lipophilic n-hexylamino group at C6 will be replaced. A (pyridin-4-ylmethyl)amino group is introduced. This retains the crucial amine linker for potential hinge binding but replaces the alkyl chain with a more rigid pyridylmethyl group. The pyridine ring can introduce favorable polar interactions, potentially improve solubility, and provide a different vector into solvent-exposed regions or adjacent pockets compared to the hexyl chain.\",\n    \"Final_Target_Molecule\": \"Cn1c(=O)c2cc(-c3c(Cl)cccc3Cl)cnc2nc1NCc1ccncc1\"\n  }\n]"
    },
    {
        "src_smiles": "CCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c1ccnc(Oc2ccccc2O)n1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features an oxadiazolone core substituted with an ethoxymethyl group, a 4-fluorophenyl ring, and a pyrimidine ring. The pyrimidine ring is further substituted with a 2-hydroxyphenoxy group.\",\n    \"Property_Analysis\": \"GSK3-beta inhibition often involves interactions with the ATP-binding site, particularly hydrogen bonding with the hinge region (e.g., Val135) and hydrophobic interactions. The source molecule possesses potential hydrogen bond donors (OH) and acceptors (N, O atoms) and aromatic rings for hydrophobic/pi-stacking interactions.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 2-hydroxyphenoxy group, while containing a hydrogen bond donor (OH), might not be optimally positioned or oriented to form strong interactions with the GSK3-beta hinge region. The flexibility of the ether linkage and the specific substitution pattern may limit potent binding.\",\n    \"Optimization_for_Source_Molecule\": \"To improve hinge binding, replace the 2-hydroxyphenoxy group (Oc2ccccc2O) with a moiety known to interact effectively with the GSK3-beta hinge. An aniline derivative, such as 3-fluoroaniline (Nc1cccc(F)c1), can introduce an NH group capable of donating a hydrogen bond to the hinge backbone carbonyl, potentially improving affinity. The fluorine substituent can modulate electronic properties and potentially engage in favorable interactions within the pocket.\",\n    \"Final_Target_Molecule\": \"CCOCn1oc(=O)c(-c2ccc(F)cc2)c1-c1ccnc(Nc2cccc(F)c2)n1\"\n  }\n]"
    },
    {
        "src_smiles": "COc1cc(Cc2cnc(N)nc2N)ccc1OCc1ccc(-c2csnn2)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a central benzene ring substituted with a methoxy group (OCH3) and a benzyloxymethyl linker (-CH2-O-CH2-phenyl). The benzyl group links to a 2,4-diaminopyrimidine core, a known kinase hinge binder. The benzyloxymethyl linker terminates with a phenyl ring substituted with a 1,3,4-thiadiazole heterocycle.\",\n    \"Property_Analysis\": \"The 2,4-diaminopyrimidine moiety is expected to interact with the hinge region of GSK3-beta via hydrogen bonds, crucial for kinase inhibition. The methoxy group and the benzyloxy-phenyl-thiadiazole portion occupy other pockets, influencing potency, selectivity, and pharmacokinetic properties. The overall structure suggests a competitive ATP inhibitor scaffold.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The 1,3,4-thiadiazole ring might be suboptimal for interactions within the GSK3-beta binding pocket or could introduce metabolic liabilities or poor physicochemical properties (e.g., solubility). The overall size and flexibility, particularly the benzyloxymethyl linker, might negatively impact binding affinity or cell permeability.\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition and drug-like properties, the terminal 1,3,4-thiadiazole group is replaced. A fluorine atom is introduced onto the terminal phenyl ring. Fluorine is often used to enhance binding affinity (potential H-bond acceptor or favorable electrostatic interactions) and improve metabolic stability without significantly increasing size.\",\n    \"Final_Target_Molecule\": \"COc1cc(Cc2cnc(N)nc2N)ccc1OCc1ccc(F)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "COCCn1c(=O)c(-c2ccc(OC)cc2)nc2cnc(OCc3ccccc3)nc21",
        "prop": "gsk",
        "json_results": "[{\n  \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrimido[4,5-d]pyrimidine core. Key substituents include a methoxyphenyl group attached to one pyrimidine ring, a benzyloxymethyl group on the fused pyrazine ring, and a methoxymethyl group on the nitrogen of the pyrimidone ring.\",\n  \"Property_Analysis\": \"The pyrimido[4,5-d]pyrimidine core likely acts as a hinge-binding motif, mimicking ATP binding to the kinase hinge region. The methoxyphenyl and benzyloxymethyl groups occupy hydrophobic pockets within the GSK3-beta active site. The pyrimidone oxygen and ring nitrogens can act as hydrogen bond acceptors/donors.\",\n  \"Limitation_in_Source_Molecule_for_Property\": \"The N-methoxymethyl group might introduce metabolic instability (ether cleavage) and may not be optimal for occupying its pocket or influencing core orientation. The benzyloxymethyl group offers flexibility but the simple benzyl ring might lack specific interactions needed for high potency or selectivity.\",\n  \"Optimization_for_Source_Molecule\": \"Replace the N1-methoxymethyl group with a more metabolically stable and potentially better-fitting ethyl group. Modify the C2-substituent by replacing the benzyl group with a 3-pyridyl group (pyridin-3-ylmethoxymethyl) to introduce a potential hydrogen bond acceptor (pyridine nitrogen) and explore interactions in that region of the binding site.\",\n  \"Final_Target_Molecule\": \"CCN1C(=O)C(-c2ccc(OC)cc2)nc2cnc(OCc3cnccc3)nc21\"\n}]"
    },
    {
        "src_smiles": "CC(NC(=O)Nc1cc2[nH]nc(OCCOC(F)(F)F)c2cn1)c1ccc(F)cc1",
        "prop": "gsk",
        "json_results": "[\n  {\n    \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a chiral center attached to a fluorophenyl ring and a urea linker. The urea connects to a pyrazolo[1,5-a]pyrimidine core, which is substituted with a 2-(2,2,2-trifluoroethoxy)ethoxy group.\",\n    \"Property_Analysis\": \"GSK3-beta inhibitors often utilize heterocyclic cores like pyrazolopyrimidines to occupy the ATP binding site. The urea group typically forms crucial hydrogen bonds with the kinase hinge region. The substituents (fluorophenyl and ether side chain) interact with adjacent hydrophobic pockets and solvent-exposed regions, influencing potency and selectivity.\",\n    \"Limitation_in_Source_Molecule_for_Property\": \"The relatively long and flexible 2-(2,2,2-trifluoroethoxy)ethoxy side chain might not provide optimal interactions within its binding pocket. Its flexibility could lead to an entropic penalty upon binding, and the specific length/fluorination pattern might not be ideal for maximizing potency or optimizing physicochemical properties (e.g., lipophilicity).\",\n    \"Optimization_for_Source_Molecule\": \"To potentially improve binding affinity and reduce lipophilicity/flexibility, the 2-(2,2,2-trifluoroethoxy)ethoxy group can be replaced with a smaller, less flexible alkoxy group, such as an isopropoxy group. This modification probes the size constraints and hydrophobic character preference of the corresponding subpocket.\",\n    \"Final_Target_Molecule\": \"CC(NC(=O)Nc1cc2[nH]nc(OC(C)C)c2cn1)c1ccc(F)cc1\"\n  }\n]"
    },
    {
        "src_smiles": "Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2cnc(NCCCN3CCOCC3)nc21",
        "prop": "gsk",
        "json_results": "[{\n  \"Structural_Analysis_of_Source_Molecule\": \"The source molecule features a pyrimido[4,5-b]azepin-4(1H)-one core. Key substituents include a methyl group on the azepine nitrogen (N1), a 2,6-dichlorophenyl group at position 6, and an N-(3-morpholinopropyl)amino group attached to the pyrimidine ring at position 2.\",\n  \"Property_Analysis\": \"The molecule possesses features common to kinase inhibitors, such as a heterocyclic core capable of hinge binding interactions and substituents targeting hydrophobic pockets and solvent-exposed regions. GSK3-beta inhibition often relies on specific hydrogen bonds with the hinge region (e.g., Asp133, Val135) and hydrophobic interactions within the ATP-binding site.\",\n  \"Limitation_in_Source_Molecule_for_Property\": \"The 2,6-dichlorophenyl group, while hydrophobic, might not be optimal for the specific shape and electronic requirements of the GSK3-beta active site pocket. Its substitution pattern could lead to steric hindrance or suboptimal hydrophobic packing. The N-(3-morpholinopropyl)amino side chain might offer too much flexibility or lack specific interactions needed for high potency against GSK3-beta. The pyrimido[4,5-b]azepin core itself might not present the pharmacophores in the most favorable geometry compared to scaffolds more commonly optimized for GSK3-beta.\",\n  \"Optimization_for_Source_Molecule\": \"To potentially improve GSK3-beta inhibition, replace the 2,6-dichlorophenyl group with a 4-pyridyl moiety. Pyridine rings are frequently found in potent GSK3-beta inhibitors (e.g., CHIR-99021 analogues) as they can engage in favorable interactions within the ATP binding site, potentially forming hydrogen bonds or improved electrostatic interactions compared to the dichlorophenyl group, while maintaining suitable size and lipophilicity.\",\n  \"Final_Target_Molecule\": \"Cn1c(=O)c(-c2ccncc2)cc2cnc(NCCCN3CCOCC3)nc21\"\n}]"
    }
]